This may include, but is not limite d to, redaction of the following: 

•Certain information  within this protocol has been redacted (ie, specific content is masked 
irreversibly from view with a black/blue bar) to protect either personally identifiable 
information 
or company confidential information. 
Named persons or organizations associated with the study.
Proprietary information, such as scales or coding systems, which are considered confidential  
information under prior agreements with license holder.
Other information as needed to protect confidentiality of Takeda or partners, personal
information, or to otherwise protect the integrity of the clinical study.Title: Title: Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4
Study Evaluating the Effect of Vortioxetine 10 and 20 mg/day vs Paroxetine 20 mg/day on Sexual
Functioning in Healthy Subjects
Study ID: [REMOVED]
Protocol Approve Date: 10 January 2017
TAKEDA PHARMACEUTICALS
PROTOCOL
A Randomized, Double -Blind, Parallel Group, Placebo -and Active -Controlled, Phase 4 
Study Evaluating the Effect of Vortioxetine 10 and 20 mg/day vs Paroxetine 20 mg/day on 
Sexual Functioning in Healthy Subjects
Effect of Vortioxetine, Paroxetine, and Placebo on Sexual Functioning
in Healthy Volunteers
Sponsor: Takeda Development Center Americas, Inc.
One Takeda Parkway
Deerfield, IL 60015
Study Number: Vorti oxetine -4001
IND Number: 76,307 EudraCT Number: Not applicable
Compound: Vorti oxetine
Amendment History : 
Date Amendment Number Amendment Type Region
11 July  2016 Initial version Not applicable United States
10 January 2017 01 Substantial United States
CONFIDENTIAL PROPERTY OF TAKEDA
This document is a confidential communication of Takeda. Acceptance of this document constitutes the agreement by 
the recipient that no information contained herein will be published or disclosed without written authorization from 
Takeda except to the extent necessary to obt ain informed consent from those persons to whom the drug may be 
administered. Furthermore, the information is only meant for review and compliance by the recipient, his or her staff, 
and applicable institutional review committee and regulatory agencies to enable conduct of the study.
Vortioxetine
Study No. Vortioxetine -4001 Page 2of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL1.0 ADMINISTRATIVE INFORMATION
1.1 Contacts 
A separate contact informat ion list will be provided to each site.
Takeda Development Center Americas, Inc. (TDC) sponsored investigators per individual country 
requi rements will be provided with emergency  medical contact inform ation cards to be carried by 
each subject.
General advice on protocol procedures should be obtained through the monitor assigned to the 
study  site. Inf ormation on service providers is given in Sect ion 3.1and relevant guidelines 
provi ded to the si te.
Contact Type/Role North America (United States) Contact
Serious adverse event and pregnancy reporting Takeda Development Center Americas, Inc.
Pharmacovigilance Department
Medical Monitor
(medical advice on protocol and study drug)
Responsible Medical Officer 
(carries overall responsibility for the conduct of the study)
PPD
Vortioxetine
Study No. Vortioxetine -4001 Page 3of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL1.2 Approval 
REPRESENTATIVES OF TAKEDA 
This study  will be conducted with the highest respect for the individual part icipants in accordance 
with the requi rements of this study  protocol  and also in accordance with the fo llowing:
Theethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applicable laws and regulat ions, including, without limitat ion, data privacy laws, c linical 
trial discl osure l aws, and regul ations.
SIGNATURES
The signature of the responsible Takeda medical officer can be found on the signature page.
Electronic Signatures are provided on the last page of this document.
Date Date
Date
PPD
PPD
PPD
Vortioxetine
Study No. Vortioxetine -4001 Page 4of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALINVESTIGATOR AGREEMENT 
I confirm that I have read and that I understand this protocol, the Invest igator’s Brochure, package 
insert, and any other product information provided by the sponsor. I agree to conduct this study in 
accordance with the requirements of this protocol and also to protect the rights, safet y, privacy, 
and well -being o f study  subjects in accordance with the following:
The ethical principles that have their origin in the Declaration of Helsinki.
International Conference on Harmonisation, E6 Good Clinical Pract ice: Conso lidated 
Guideline.
All applica ble laws and regulat ions, including, without limitat ion, data privacy laws and 
regul ations.
Regulatory  requi rements for reporting serious adverse events defined in Sect ion10.2 of this 
protocol .
Terms outlined in the study  site agreement.
Appendix B–Responsibilit ies o f the Invest igator.
I further authorize that my personal informat ion may be processed and transferred in accordance 
with the uses contem plated in Appendix Dof this protocol .
Signature of Investi gator Date
Invest igator Name (print or ty pe)
Invest igator’s Tit le
Locati on of  Facilit y (Ci ty, State/Provence)
Locati on of  Facilit y (Country )
Vortioxetine
Study No. Vortioxetine -4001 Page 5of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL1.3 Protocol Amendment 01Summary of Changes
This document describes the changes in reference to the Proto col Incorporating Amendment 
No.01.
The primary  purpose of thi s amendment is to update the protocol regarding eligibilit y criteria. 
Other minor changes in procedures are proposed. Minor grammat ical and editorial changes are 
included for clarificat ion purposes only . Full details on changes of text are given in Appendix F, 
including de tailed rati onale . The foll owing i s a summary  of the changes made in the amendment:
1.
Clarify inclusi on and exclusio n criteria. 
2.Update, correct, or clarify  excl uded m edicat ions and treatments .
3.Add that psy chiatri c history  will be assessed as well as medical history .
4.Add instructi ons on the order in which the scales Changes in Sexual Funct ioning 
Quest ionnaire Short -Form  (CSFQ -14) and Patient Global Impressio n of Im provement (PGI -I) 
shoul d be com pleted . 
5.Update personnel changes .
Vortioxetine
Study No. Vortioxetine -4001 Page 6of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALTABLE OF CONTENTS
1.0 ADMINISTRATIVE INFOR MATION ........................................................................... 2
1.1 Contacts ..................................................................................................................... 2
1.2 Approval .................................................................................................................... 3
1.3 Protocol  Ame ndment 01 Summary  of Changes .......................................................... 5
2.0 STUDY SUMMARY .................................................................................................... 11
3.0 STUDY REFERENCE INFO RMATION ...................................................................... 16
3.1 Study -Related Responsibilit ies................................................................................. 16
3.2 Coordinat ing Investigator ......................................................................................... 16
3.3 List of Abbreviat ions............................................................................................... 17
3.4 Corporate Identificat ion........................................................................................... 18
4.0 INTRODUCTION ......................................................................................................... 19
4.1 Background ............................................................................................................. 19
4.2 Rationale for the Proposed Study ............................................................................. 20
5.0 STUDY OBJECTIVES AND ENDPOINTS .................................................................. 21
5.1 Object ives................................................................................................................ 21
5.1.1 Primary Object ive.............................................................................................. 21
5.1.2 Secondary  Object ives......................................................................................... 21
5.1.3 Addit ional Objectives ......................................................................................... 21
5.1.4 Safety Objective .................................................................................................21
5.2 Endpoints ................................................................................................................. 21
5.2.1 Primary Endpo int............................................................................................... 21
5.2.2 Secondary  Endpo ints.......................................................................................... 21
5.2.3 Addit ional Endpo ints......................................................................................... 22
5.2.4 Safety Assessments ............................................................................................ 22
6.0 STUDY DESIGN AND DES CRIPTION ....................................................................... 23
6.1 Study  Design ........................................................................................................... 23
6.2 Justification for Study Design, Dose, and Endpoints ................................................ 24
6.2.1 Study  Design ...................................................................................................... 24
6.2.2 Dose .................................................................................................................. 24
6.2.3 Endpoints ........................................................................................................... 25
6.3 Prem ature Terminat ion or Suspension o f Study  or Study  Sites.................................25
6.3.1 Criteria for Premature Terminat ion or Suspension of the Study .......................... 25
6.3.2 Criteria for Premature Terminat ion or Suspension of Study  Sites....................... 25
Vortioxetine
Study No. Vortioxetine -4001 Page 7of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL6.3.3 Procedures for Premature Termination or Suspension of the Study  or the 
Parti cipation of  Study  Sites................................................................................ 26
7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS .............. 27
7.1 Inclusio n Cri teria..................................................................................................... 27
7.2 Exclusio n Cri teria.................................................................................................... 27
7.3 Excluded Medicat ions and Treatments ..................................................................... 29
7.4 Criteria for Di scontinuati on or Wi thdrawal  of a Subject ........................................... 32
7.5 Procedures for Discont inuat ion or Withdrawal o f a Subject ...................................... 33
8.0 CLINICAL STUDY MATER IAL MANAGEMENT ..................................................... 34
8.1 Study  Drug and Materials ........................................................................................ 34
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling ..................................... 34
8.1.1.1 Study  Drug .............................................................................................. 34
8.1.1.2 Sponsor -Supplied Drug ............................................................................ 35
8.1.2 Storage ............................................................................................................... 35
8.1.3 Dose and Regimen ............................................................................................. 35
8.1.4 Overdose ............................................................................................................ 36
8.2 Study  Drug Assignment and Dispensing Procedures ................................................ 36
8.3 Randomization Code Creation and Storage .............................................................. 37
8.4 Study  Drug Blind Maintenance ................................................................................ 37
8.5 Unblinding Procedure .............................................................................................. 37
8.6 Accountabilit y and Destruction of Sponsor -Supplied Drugs ..................................... 38
9.0 STUDY PLAN .............................................................................................................. 40
9.1 Study  Procedures ..................................................................................................... 40
9.1.1 Inform ed Consent Procedure .............................................................................. 40
9.1.2 Subject Database and Authorizat ion................................................................... 40
9.1.3 Dem ographics, Medi cal History , Psy chiatri c History , and Medicat ion History  
Procedure ........................................................................................................... 40
9.1.4 Physical Examinat ion Procedure ........................................................................ 41
9.1.5 Weight, Height, and BMI ................................................................................... 41
9.1.6 Vital Sign Procedure .......................................................................................... 41
9.1.7 ECG Procedure .................................................................................................. 41
9.1.8 Sexual Functioning Assessments ........................................................................ 42
9.1.8.1 CSFQ -14.................................................................................................42
9.1.8.2 PGI-I Scale .............................................................................................. 42
9.1.9 C-SSRS .............................................................................................................. 42
Vortioxetine
Study No. Vortioxetine -4001 Page 8of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL9.1.10 Docum entati on of  Conco mitant Medi cations...................................................... 42
9.1.11 Docum entati on of  Concurrent Medi cal and/or Psy chiatri c Condi tions................ 42
9.1.12 Procedures for Clinical Laboratory  Samples ....................................................... 43
9.1.13 Contraception and Pregnancy Avo idance Procedure ........................................... 45
9.1.14 Pregnancy .......................................................................................................... 46
9.1.15 PGx Sample Co llection...................................................................................... 47
9.1.16 PK Sam ple Collect ion and Analysis ................................................................... 48
9.1.16.1 Collect ion of Plasma for PK Sampling ..................................................... 48
9.1.16.2 Bioanaly tical Methods ............................................................................. 48
9.1.17 Docum entati on of  Screen Failure ....................................................................... 48
9.1.18 Docum entati on of  Rescreening ........................................................................... 49
9.1.19 Docum entati on of  Study  Entrance ...................................................................... 49
9.2 Moni toring Subject Treatment Compliance .............................................................. 49
9.3 Schedule of Observat ions and Procedures ................................................................ 50
9.4 Biological Sample Retent ion and Destruction .......................................................... 50
10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS ............................................ 51
10.1 Definit ions............................................................................................................... 51
10.1.1 PTEs .................................................................................................................. 51
10.1.2 AEs.................................................................................................................... 51
10.1.3 Addit ional Po ints to Consider for PTEs and AEs ................................................ 51
10.1.4 SAEs .................................................................................................................. 53
10.1.5 Special Interest Adverse Events ......................................................................... 54
10.1.5.1 Skin and Allergic Ty pe React ions............................................................ 54
10.1.5.2 Liver Injury ............................................................................................. 55
10.1.5.3 Overdose .................................................................................................55
10.1.6 Intensit y of PTEs and AEs ................................................................................. 56
10.1.7 Causalit y of AEs................................................................................................ 56
10.1.8 Relationship to Study  Procedures ....................................................................... 56
10.1.9 Start Date ........................................................................................................... 56
10.1.10 Stop Date ..................................................................................................... 56
10.1.11 Frequency .................................................................................................... 56
10.1.12 Action Concerning Study  Drug .................................................................... 56
10.1.13 Outcom e....................................................................................................... 57
10.2 Procedures ............................................................................................................... 57
10.2.1 Collect ion and Reporti ng of AEs........................................................................ 57
Vortioxetine
Study No. Vortioxetine -4001 Page 9of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL10.2.1.1 PTE and AE Reporting ............................................................................ 57
10.2.1.2 Speci al Interest Adverse Event Reporting ................................................ 58
10.2.2 Collect ion and Reporti ng of SAEs ...................................................................... 59
10.2.3 Reporting of Abnormal LFTs ............................................................................. 59
10.3 Follow-up of  SAEs .................................................................................................. 59
10.3.1 Safety Reporting to Invest igators, IRBs, and Regulatory  Authori ties.................. 60
11.0 STUDY -SPECIFIC COMMITTEES ............................................................................. 61
12.0 DAT A HANDLING AND RE CORDKEEPING ............................................................ 62
12.1 Case Report Forms (Electronic) ............................................................................... 62
12.2 Record Retention ..................................................................................................... 62
13.0 STATISTICAL METHODS .......................................................................................... 64
13.1 Statistical and Analyt ical Plans ................................................................................ 64
13.1.1 Analysis Sets ...................................................................................................... 64
13.1.2 Analysis of Demographics and Other Baseline Characterist ics........................... 64
13.1.3 Efficacy Analysis ............................................................................................... 65
13.1.3.1 Primary Analysis ..................................................................................... 65
13.1.3.2 Secondary  Analyses ................................................................................. 65
13.1.3.3 Addit ional Analyses ................................................................................ 65
13.1.4 PK Analysis ....................................................................................................... 66
13.1.5 PGx Analysis ..................................................................................................... 66
13.1.6 Safety Analysis .................................................................................................. 66
13.2 Interim Analysis and Criteria for Early Terminat ion................................................ 66
13.3 Determinat ion of Sample Size .................................................................................. 66
14.0 QUALITY CONTROL AND QUALITY ASSURANCE ............................................... 68
14.1 Study -Site Moni toring Visit s................................................................................... 68
14.2 Protocol  Deviat ions.................................................................................................. 68
14.3 Qualit y Assurance Audits and Regulatory  Agency  Inspect ions................................ 68
15.0 ETHICAL ASPECTS OF T HE STUDY ........................................................................ 69
15.1 Institutional Review Board Approval ....................................................................... 69
15.2 Subject Informat ion, Inform ed Consent, and Subject Authorizat ion......................... 70
15.3 Subject Confidentialit y............................................................................................ 71
15.4 Publicat ion, Di sclosure, and Clinical Trial Registration Policy .................................71
15.4.1 Publicat ion and Disclosure ................................................................................. 71
15.4.2 Clinical Trial Registration .................................................................................. 72
15.4.3 Clinical Trial Result s Disclosure ........................................................................ 72
Vortioxetine
Study No. Vortioxetine -4001 Page 10of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL15.5 Insurance and Co mpensation for Injury .................................................................... 72
16.0 REFERENCES .............................................................................................................. 73
LIST OF IN -TEXT TABLES
Table 7.a Excluded Medicat ions and Treatments ............................................................... 30
Table 8.a Dose and Regimen ............................................................................................. 36
Table9.a Approximate Blood Volume .............................................................................. 43
Table 9.b Clinical Laboratory  Tests ................................................................................... 44
Table 10.a Takeda Medically Significant AE List ................................................................ 54
LIST OF IN -TEXT FIGURES
Figure 6.a Schemat ic of Study  Design ................................................................................ 24
LIST OF APPENDICES
Appendix A Schedule of Study  Procedures ............................................................................ 75
Appendix B Responsibilit ies o f the Invest igator ..................................................................... 77
Appendix C Elements of the Subject Informed Consent ......................................................... 79
Appendix D Invest igator Consent to Use of Personal Informat ion.......................................... 82
Appendix E Collect ion, Storage, and Ship ment of Pharmacokinetic Samples ......................... 83
Appendix F Detailed Descript ion of Amendments to Text ..................................................... 85
Vortioxetine
Study No. Vortioxetine -4001 Page 11of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL2.0 STUDY SUMMARY
Name of Sponsor:
Takeda Development Center Americas, Inc.Compound:
Vortioxetine
Title of Protocol: A Randomized, Double -Blind, Parallel Group, 
Placebo -and Active -Controlled, Phase 4 Study Evaluating the 
Effect of Vortioxetine 10 and 20 mg/day vs Paroxetine 20 mg/day 
on Sexual Functioning in Healthy SubjectsIND No.:
76,307EudraCT No.:
Not applicable
Study Number: Vortioxetine -4001 Phase: 4
Study Design:
This is a phase 4, multicenter, randomized, double -blind, placebo -and active -controlled (paroxetine), 4-arm, parallel 
group, fixed -dose study comparing the effect of vortioxetine (10 and 20 mg once daily [QD]) vs paroxetine (20 mg 
QD) on sexual functionin g after 5 weeks of treatment in healthy adult men and women. This outpatient study will be 
conducted at approximately 15 sites in North America. Men and women will be enrolled in approximately equal 
proportions (ie, 50% men and 50% women, overall). Enrollm ent will be capped for each sex when the enrollment 
target has been met for that sex stratum.
Subjects will enter a Screening Period of up to 4 weeks. At Baseline (Day 0), eligible subjects will be equally (1:1:1:1) 
randomized to double -blind vortioxetine 10 mg, vortioxetine 20 mg, paroxetine 20 mg, or placebo and will be treated 
for 5 weeks. Randomization will be stratified by sex. Subjects allocated to vortioxetine 20 mg will initiate treatment at 
10mg/day  for the first week. Subsequently, the dose will be increased to 20 mg/day and remain at 20 mg/day until 
study completion. Subjects allocated to vortioxetine 10 mg will initiate treatment at 10 mg/day and remain at 
10mg/day  until study  completion. Subjects allocated to paroxetine 20 mg will initiate tre atment at 20 mg/day  and 
remain at 20 mg/day  until study completion. Subjects will be instructed to take their first dose of study drug the day 
after Baseline on Day 1, preferably in the morning. After randomization, subjects will be seen for weekly visits and 
receive a follow -up safety contact by telephone 2 weeks after the end of double -blind treatment. At the end of 5 weeks 
of treatment, or at early termination (ET), all subjects will abruptly discontinue study drug.
Sexual functioning will be assessed at each study visit using the CSFQ -14 (primary variable). The PGI -I scale will be 
administered at each study visit except at Screening and Baseline. Signs of suicidal risk will be assessed at each study 
visit using the Columbia -Suicide Severity Rating Scale (C-SSRS) and the investigator’s clinical judgment. Safety will 
be assessed throughout the study. A total of 6 sparse pharmacokinetic (PK) samples (trough samples) will be collected 
to measure plasma vortioxetine or paroxetine concentrations at Weeks 3, 4, and 5/ET (2 samples at each time point). A 
pharmacogenomic (PGx) blood sample for deoxyribonucleic acid (DNA) isolation will be collected predose at 
Baseline (Day 0), and 2 PGx blood samples for ribonucleic acid (RNA) isolation will be collected predose at Baseline 
(Day  0) and also at Week 5/ET (ie, 4 samples per subject). 
Primary Objective:
To evaluate the effect of vortioxetine (10 and 20 mg QD) vs paroxetine 20 mg QD on sexual functioning in 
healthy  subjects after 5 weeks of double -blind treatment. 
Secondary Objectives:
To evaluate the effect of vortioxetine (10 and 20 mg QD) vs paroxetine 20 mg QD on sexual functioning in 
healthy  subjects throughout the 5 -week double -blind Treatment Period.
To evaluate the effect of paroxetine (20 mg QD) vs placebo on sexual functioning in healthy subjects throughout 
the 5 -week double -blind Treatment Period.
To evaluate the effect of vortioxetine (10 and 20 mg QD) vs placebo on sexual functioning in healthy subjects 
throughout the 5 -week double -blind Treatment Period .
Vortioxetine
Study No. Vortioxetine -4001 Page 12of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAdditional Objectives:
To evaluate the effects of vortioxetine (10 and 20 mg QD) vs paroxetine (20 mg QD) on additional parameters of 
sexual functioning.
To evaluate the effect of vortioxetine (10 and 20 mg QD) and paroxetine (20 mg QD) vs placebo on ad ditional 
parameters of sexual functioning.
To evaluate the subject’s perception of sexual functioning. 
To assess the treatment effect (vortioxetine, paroxetine, or placebo) on suicidal ideation and behavior. 
Safety Objective:
To evaluate the safety and tolerability of vortioxetine (10 and 20 mg QD) and paroxetine (20 mg QD) vs placebo.
Subject Population: Healthy  men and women aged 18 to 40 years, inclusive.
Number of Subjects:
Per each of 4 treatment arms: 88
Estimated total: 352Number of Sites: 
Approximately 15 sites in North America
Dose Levels:
Vortioxetine 10 mg
Vortioxetine 20 mg
Paroxetine 20 mg
PlaceboRoute of Administration:
Oral
Duration of Treatment:
Single dose QD for 5 weeksPeriod of Evaluation:
5 weeks, plus a 2-week follow -up
Main Criteria for Inclusion:
The subject is a healthy male or female aged 18 to 40 years, inclusive.
The subject has been in a steady relationship for ≥3months and plans to remain in that relationship for the 
duration of the study, and is currently sexual ly active ( ≥2times per week). Note: Partners are not allowed to enroll 
in this trial.
The subject has a body mass index of 18 to 35 kg/m2, inclusive, at the Screening and Baseline Visits.
If female, the subject has a regular menstrual cycle (note: amenorrhea resulting from hormonal contraceptives is 
not exclusionary) .
The subject has normal sexual functioning, as defined by a CSFQ -14 total score >47 (men) or >41 (women) at the 
Screening and Baseline Visits. 
If female, the subject taking allowed hor monal contraceptives is on a stable dose for ≥3months prio r to the 
Baseline Visit and continues on the stable dose for the duration of the study. 
Main Criteria for Exclusion:
The subject has a clinically significant unstable illness or a history of depr ession or any other psychiatric illness.
The subject is positive for hepatitis B surface antigen, anti –hepatitis C virus antibodies, or human 
immunodeficiency virus at the Screening Visit or has any known sexually transmitted diseases.
The subject has a kn own history of or currently has increased intraocular pressure or is at risk of acute 
narrow -angle  glaucoma.
The subject has a significant risk of suicide according to the investigator’s clinical judgment, or has made a 
suicide attempt at any  time .
The sub ject has current sexual dysfunction, or a history of a diagnosis or treatment of sexual dysfunction.
Vortioxetine
Study No. Vortioxetine -4001 Page 13of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALThe subject has had a surgical or medical procedure on reproductive/genitourinary organs (excluding 
uncomplicated cesarean section ( C-section), vasectomy ,and tubal ligation that do not impact sexual function ).
If female, the subject has polycystic ovarian syndrome.
The subject has hypogonadism or has a free testosterone value outside the normal range at the Screening Visit that 
is indicative of hypogonadis m.
The subject has a history of or current alcohol or other substance abuse or dependence (according to the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition , Text Revised [DSM-IV -TR]criteria) .
The subject has habitual tobacco or other nicotine usage (equivalent to ≥10 cigarettes per day).
Main Criteria for Evaluation and Analyses:
Primary Endpoint
Change f rom Baseline in the CSFQ -14 total score difference for vortioxetine vs paroxetine after 5 weeks of 
treatment.
Secondary Endpoints
Change from Baseline in the CSFQ -14 total score difference for vortioxetine vs paroxetine at each visit assessed.
Change f rom Baseline in CSFQ -14 total score difference for paroxetine vs placebo at each visit assessed.
Change f rom Baseline in CSFQ -14 total score difference for vortioxetine vs placebo at each visit assessed. 
Percentage of subjects meeting criteria for sexual dysfunction (ie, CSFQ -14 total score ≤47 for men and ≤41 for 
women) at any visit during the 5 -week double -blind Treatment Period.
Chan ge from Baseline in CSFQ -14 subscales 5 dimensions (pleasure, desire/frequency, desire/interest, 
arousal/erection, and orgasm/ejaculation) and 3 phases of the sexual response cycle (desire, arousal, and 
orgasm/completion) at each visit assessed.
Additional Endpoints
Percentage of subjects meeting criteria for sexual dysfunction (ie, CSFQ -14 total score ≤47 for men and ≤41 for 
women) at any 2 consecutive visits during the 5 -week double -blind Treatment Period.
Time to sexual dysfunction as assessed by the CSF Q-14.
Percentage of subjects with a shift in the CSFQ -14 from normal (ie, CSFQ-14 total score >47 for men and >41 for 
women) at Baseline to abnormal (ie, CSFQ -14 total score ≤47 for men and ≤41 for women) at each visit assessed.
Percentage of subjects show ing decreased sexual function (ie, negative responders) according to the CSFQ -14 (ie, 
CSFQ -14 total score decrease from Baseline ≥3) at each visit assessed.
PGI-I score at each visit assessed.
C-SSRS at each visit assessed.
Safety Assessments
Adverse event s (AEs), vital signs, clinical laboratory tests, weight, and physical examinations.
Statistical Considerations:
Primary Analysis
Mean change from Baseline in the CSFQ -14 total score difference for vortioxetine vs paroxetine after 5 weeks of 
treatment will be the primary endpoint. The primary analysis will be based on analysis of covariance (ANCOVA) 
using the last observation carried forward (LOCF) technique, with treatment, center, and sex as fixed factors, and 
baseline CSFQ -14 total score as covariate. The comparisons will be between each vortioxetine dose (10 or 20 mg) and 
paroxetine, and both statistical tests will be 2 -sided. The Holm -Bon ferro ni method will be used to adjust for 
multiplicity and control the familywise type I error rate at a significance level of 0.05. If the smaller of the 2 p -values 
is <0.025, significance is obtained for the associated vortioxetine dose and the other dose will then be evaluated at a 
0.05 significance level. Although vortioxetine will be compared with paroxetine in the primary analysis, paroxetine 
Vortioxetine
Study No. Vortioxetine -4001 Page 14of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALwill also be compared with placebo to validate the study.
Secondary Analyses
Change f rom Baseline in CSFQ -14 total score for vortioxetine vs paroxetine, paroxetine vs placebo, and vortioxetine 
vs placebo at each visit will also be analyzed using ANCOVA and LOCF, with treatment, center, and sex as fixed 
factors, and baseline CSFQ -14 total score as covariat e. Similar analyses will also be performed for the male and 
female subgroups. Comparisons to placebo will be made at the significance level of 0.05 outside of multiplicity 
control.
The percentage of subjects meeting criteria for sexual dysfunction (ie, CSF Q-14 total score ≤47 for men and ≤41 for 
women) at any visit (using LOCF) during the double -blind Treatment Period will be analyzed by logistic regression, 
adjusting for baseline CSFQ -14 total score, sex, and treatment.
Change from Baseline in CSFQ -14 subs cales 5 dimensions and 3 phases of the sexual response cycle will be analyzed 
at all visits using ANCOVA and LOCF similar to the primary analysis.
Additional Analyses
The percentage of subjects meeting criteria for sexual dysfunction (ie, CSFQ -14 total sco re ≤47 for men and ≤41 for 
women) at any 2 consecutive visits (using LOCF) during the double -blind Treatment Period will be analyzed by 
logistic regression, adjusting for baseline CSFQ -14 total score, sex, and treatment.
Time to sexual dysfunction as asses sed by the CSFQ -14 will be analyzed using a Cox model with an exact method to 
handle ties, with treatment and sex as factors.
CSFQ -14 shift f rom normal (ie, CSFQ -14 total score >47 for men and >41 for women) at Baseline to abnormal 
(ie,CSFQ -14 total score ≤47 for men and ≤41 for women), and CSFQ -14 n egative responders (decrease from Baseline 
in CSFQ -14 total score ≥3) will be analyzed at all visits by logistic regression, adjusting for baseline CSFQ -14 total 
score, sex, and treatment.
PGI-I will be analyze d by study  visit using ANCOVA and LOCF, with treatment, center, and sex as fixed factors.
C-SSRS will be summarized by study visit for each treatment group using descriptive statistics.
Safety Analyses
AEs will be coded using the Medical Dictionary for Reg ulator y Activities (MedDRA) and will be summarized by 
system organ class and preferred term for the double -blind Treatment Period and the entire study. AEs that were 
reported more than once by a subject during the double -blind Treatment Period will be coun ted only  once for that 
subject at the maximum severity.
Absolute values and changes from Screening/Baseline for clinical laboratory tests, vital signs, and weight will be 
summarized for each treatment group using descriptive statistics. Clinical laboratory test and vital sign results that are 
outside the normal ranges and potentially clinically significant will be flagged and tabulated. Physical examination 
findings will also be summarized for each treatment group.
PK Analysis
Plasma concentrations of vortioxetine and paroxetine will be presented in the data listings. A population PK analysis 
will only be conducted if deemed necessary. If this analysis is conducted, the results will be reported in a separate 
populatio n PK report.
PGx Analysis
DNA sample s may be used to understand the mode of action of vortioxetine, and RNA samples may be used for 
subsequent pathway analysis. Also, since PGx is an evolving science, many genes and their functions are not yet fully 
understood. Future data may suggest a role of some of these genes in drug response, which may lead to additional 
hypothesis -generating exploratory research and diagnostic development using stored samples.
Vortioxetine
Study No. Vortioxetine -4001 Page 15of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALSample Size Justification: 
Approximately 352 male and female subjects will be randomized to 4 treatment arms.
Assuming an SD of 8.5 for the change from Baseline in CSFQ -14 total score, a total of 352 male and female subjects 
(88 subjects per arm) is sufficient to achieve ≥80% power to detect a difference of 4.0 for vortioxetine 20 mg vs 
paroxeti ne 20 mg or for vortioxetine 10 mg vs paroxetine 20 mg by a 2 -sample t -test with a 0.025 2 -sided significance 
level. Given the proposed Holm -Bon ferroni method for multiplicity control, the power to achieve the significance for 
each vortioxetine dose is app roximately 85%.
Vortioxetine
Study No. Vortioxetine -4001 Page 16of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL3.0 STUDY REFERENCE INFO RMATION
3.1 Study -Related Responsibilities 
The sponsor will perform all study -related activit ies wi th the except ion of those i dentified in the 
Study -Related Responsibilit ies tem plate. The i dentified vendors in the template for specific 
study -related activit ies will perform  these act ivities in full or in partnership with the sponsor.
3.2 Coordinating Investigator
Takeda will select a Signatory Coordinating Investigator fro m the invest igators who participate in 
the study . Selection criteria for thi s investi gator will include significant knowledge of the study  
protocol , the study drug, their expert ise in t he therapeutic area and the conduct of clinical research, 
as well as study  parti cipati on. The Si gnatory  Coordinat ing Inve stigator will be required to review 
and sign the clinical study  report and by doing so agrees that it accurately describes the results of 
the study .
Vortioxetine
Study No. Vortioxetine -4001 Page 17of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL3.3 List of Abbreviations
5-HT 5-hydroxy tryptamine (serotonin)
AE adverse event
ALT alanine aminotransferase
ANCOVA analy sis of covariance
ASEX Arizona Sexual Experiences Scale
AST aspartate aminotransferase
BMI body mass index
C-section cesarean section
CFR Code of Federal Regulations
CSFQ -14 Changes in Sexual Functioning Questionnaire Short -Form
C-SSRS Columbia -Suicide Severity Rating Scale
DNA deoxyribonucleic acid
DRESS drug reaction with eosinophilia and systemic symptoms
DSM -IV-TR Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revised
ECG electrocardiogram
eCRF electronic case report form 
ET Early  Termination
FAS full analy sis set
FDA Food and Drug Administration
GCP Good Clinical Practice
GGT -glutamy l transferase
HbA1c glycosylated hemoglobin
HBr hydrobromide
HBsAg hepatitis B surface antigen
hCG human chorionic gonadotropin
HCV hepatitis C virus
HIPAA Health Insurance Portability and Accountability Act
HIV human immunodeficiency virus
ICH International Conference on Harmonisation
ID identification
INR internatio nal no rmalized ratio
IRB institutional review board
IUD intrauterine device
IWRS interactive web response system
K2EDTA potassium ethylenediamine tetraacetic acid
LFT liver function tests
LOCF last observation carried forward
MedDRA Medical Dictionary for Regulatory Activiti es
MDD major depressive disorder
Vortioxetine
Study No. Vortioxetine -4001 Page 18of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALOE overencapsulated
PGI-I Patient Global Impression of Improvement
PGx pharmacogenomic(s)
PK pharmacokinetic(s)
PPS per-protocol analysis set
PTE pretreatment event
QD once daily
RCF relative centrifugal force
RNA ribonucleic acid
SAE serious adverse event
SJS Stevens -Johnson syndrome
SMS short message service
SSRI selective serotonin reuptake inhibitor
SUSAR suspected unexpected serious adverse reaction
T4 thyroxine
TEN toxic epidermal necrolysis
TESD treatment -emergent sexual dysfunction
TSH thyroid-stimulating hormone
ULN upper limit of normal
US United States
USP United States Pharmacopeia
WHO World Health Organization
3.4 Corporate Identification
TCAL Takeda California, Inc.
TDC Americas Takeda Development Center Americas , Inc.
TDC TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Takeda TDC Japan, TDC Asia, TDC Europe and/or TDC Americas, as applicable
Vortioxetine
Study No. Vortioxetine -4001 Page 19of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL4.0 INTRODUCTION
4.1 Background
The prevalence of major depressive disorder (MDD) in the United States is 8.3%, based on a 
recent World Healt h Organizat ion (WHO) World Mental Health survey [1]. Furthermore, the 
burden is likely to grow over the coming years. According to the WHO, depressio n alone accounts 
for 4.3% of the global burden o f disease and is among the largest single causes of disabilit y 
worldwide (11% of all years li ved wi th disabili ty globally), parti cularly  for wom en [2].
Depressio n poses an econo mic burden on the patients, their families and friends, and society. The 
abilit y of depressed pat ients or their caregivers to work and m ake productive contributions to the 
economy is reduced, whereas the utilization of treatment and support services is increased. The 
economic consequences of these healt h losses are significant: a recent study  estimated that the 
cumulative glo bal impact of m ental  disorders in terms of lost economic output will amount to 
US$ 16.3 millio n between 2011 and 2030 [2]. 
Unfortunately, most of the currently available ant idepressants produce sexual dysf unction in men 
and wo men and affect all phases of sexual act ivity by decreasing desire, arousal, orgasm, and 
ejaculat ion [3-7]. Such si de effects affect the patient’s qualit y of life, can lead to therapeuti c 
nonco mpliance, and often interfere with recovery  from a depressive episode [4,8-10] . In a study  
conducted by  Hu et al  (2004) [11], patients receiving antidepressant treatment were asked to rank 
which of the side effects they  experienced were the most bothersome. In this population, sexual 
dysfunct ion was ranked as the most bothersome ad verse event (AE), followed by 
drowsiness/fat igue, weight gain, and insomnia.
Despite being co mmo n, ant idepressant -related sexual dysfunct ion is one of the most under 
reported AEs [11,12]. In a study  by Montej o-Gonzalez et al (1 997), only 14% of the patients 
spontaneously reported sexual -related AEs; when elicited by direct question, however, as many as 
58% of these patients reported sexual dysfunct ion [13].
Using an object ive measurement to assess the rate of sexual dysfunction in a sample of individuals 
receiving ant idepressant monotherapy, Clayton and Montejo (2006) [14] found that the prevalence 
of sexual dysfunctio n was on average 24% (ranging fro m 7% to 30%, depending on the 
medicat ion).
Vorti oxetine is an ant idepressant agent approved in 66 countries worldwide, including in the 
United States (US) and the European Union since 2013, for treatment of MDD. It differs from 
preexist ing antidepressants in that it combines 2 pharmaco logical m odes of act ion: direct 
modulat ion of 5 -hydroxy tryptamine (5 -HT) (serotonin) receptor activit y and inhibit ion of the 
5-HT transporter. Vortioxet ine is an antagon ist at 5-HT 3, 5-HT 7, and 5-HT 1Dreceptors, an agonist 
at 5-HT 1Areceptors, a partial agonist at 5 -HT 1Breceptors, and an inhibitor of the 5 -HT transporter 
[15,16].
During the clinical development program, the efficacy , safet y, and tol erabili ty of vorti oxetine in 
subjects wi th MDD was evaluated at doses fro m 1 to 20 m g/day  in short -term efficacy studi es of  
6to 8weeks’ duration and long -term safety studi es up to 52 w eeks’ duration. Vortioxetine was 
Vortioxetine
Study No. Vortioxetine -4001 Page 20of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALsafe and well -tolerated across the dose range evaluated. The efficacy of vortioxetine in the 
treatm ent of subjects with MDD was established in 6 randomized, double -blind, 
placebo -controlled, fixed- dose, 6 -to 8-week studies (including 1 study  in the elderly). Efficacy  
was established at doses of 5, 10, 15 and 20 mg, wit h the recommended starting dose being 
10mg/day [17]. 
The l ong-term efficacy  and mainten ance of effect of vortioxet ine treatment at doses of 5 and 
10mg/day have been previ ously  established in subjects with MDD [18].
4.2 Rationale for the Proposed Study
Treatment with ant idepressants, particularly selective serotonin reuptake inhibitors (SSRIs), may 
be associ ated wi th sexual dysfunct ion including AEs at virt ually all phases of sexual response 
(ie,desire, arousal , and orgasm ), which can frequent ly result in poor treatment compliance and 
even ant idepressant treatment discont inuat ion [5].Results fro m phase 3 studies in acute depressed 
subjects indicate that vortioxet ine is associated with less treatment -emergent sexual dysfunct ion 
(TESD) when co mpared with duloxetine, and i s similar to placebo at the 5 and 10 mg doses, as 
assessed by  data collected prospectively ut ilizing the Arizona Sexual Experiences Scale (ASEX) 
and by  spontaneous reports of AEs during 8 weeks of treatment [17].
A subsequent study  was conducted to evaluate the effects of vortioxet ine in improving 
antidepressant -associ ated sexual dysfunct ion compared with another antidepressant using an 
objective measure, the Changes in Sexual Funct ioning Quest ionnaire Short -Form  (CSFQ -14). In 
this study , adul t subjects wi th MDD whose depressive symptoms were well treated with 1 of 
3SSRIs, citalopram, sertraline, or citalopram, but who had abnormal sexual functioning, as 
assessed by  the CSFQ -14, which in t he invest igator’s opinio n was attributed to the subject’s 
current SSRI treatment, were switched to vortioxetine or escitalopram. Vortioxet ine was 
statist ically significant ly superior to escitalopram in improving SSRI -induced sexual dysfunct ion 
as measured by the CSFQ- 14 total  score at Week 8 [19].
The obj ective o f the current study  is to further evaluate the effects of vortioxet ine on sexual 
funct ioning as compared wit h paroxetine, an SSRI known to cause sexual dysfunct ion, in healt hy 
subjects after 5 weeks of treatment. 
Pharmacogeno mic (PGx) analy sis may  be conducted to evaluate the contribut ion of genet ic 
variance on drug response (eg, safet y and tol erability ). The sam pling of whol e blood for PGx 
analysis is mandatory; every  subject m ust consent to this procedure to participate in this study .
Vortioxetine
Study No. Vortioxetine -4001 Page 21of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL5.0 STUDY OBJECTIVES AND END POINTS
5.1 Objectives
5.1.1 Primary Objective 
To evaluate the effect of vortioxet ine (10 and 20 mg once daily [QD]) vs paroxet ine 20 mg QD 
on sexual functioning in healt hy subjects after 5 weeks of double -blind treatment. 
5.1.2 Secondary Objectives
To evaluate the effect of vortioxetine (10 and 20 mg QD) vs paroxetine 20 mg QD on sexual 
funct ioning in healt hy subjects throughout the 5 -week double -blind Treatment Period.
To evaluate the effect of paroxetine (20 mg QD) vs placebo on sexual funct ioning i n healt hy 
subjects throughout the 5- week double -blind Treatment Period.
To evaluate the effect of vortioxetine (10 and 20 mg QD) vs placebo on sexual funct ioning in 
healt hy subjects throughout the 5- week double -blind Treatm ent Pe riod.
5.1.3 Additional Objectives
To evaluate the effects of vortioxet ine (10 and 20 mg QD) vs paroxetine (20 mg QD) on 
additional parameters of sexual funct ioning.
To evaluate the effect of vortioxetine (10 and 20 mg QD) and paroxetine (20 mg QD) vs 
placebo on addi tional parameters of s exual  functioning.
To evaluate the subject’s percept ion of sexual functioning. 
To assess the treatment effect (vortioxet ine, paroxetine, or placebo) on suicidal ideat ion and 
behavior. 
5.1.4 Safety Objective
To evaluate the safet y and tol erabili ty of vorti oxetine (10 and 20 mg QD) and paroxetine 
(20mg QD) vs placebo.
5.2 Endpoints
5.2.1 Primary Endpoint
Change from Baseline in the CSFQ -14 total  score difference for vortioxetine vs paroxet ine 
after 5 weeks of treatment.
5.2.2 Secondary Endpoints
Change from Baseline in the CSFQ -14 total  score difference for vortioxetine vs paroxet ine at 
each visit assessed.
Vortioxetine
Study No. Vortioxetine -4001 Page 22of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALChange from Baseline in CSFQ -14 total score difference for paroxetine vs placebo at each visit  
assessed.
Change from Baseline in CSFQ -14 total  score difference for vortio xetine vs placebo at each 
visit assessed. 
Percentage of subjects meet ing cr iteria for sexual dysfunct ion (ie, CSFQ -14 total score ≤47 for 
men and ≤41 for wom en) at any  visit during the 5 -week double -blind Treatment Period.
Change from Baseline in CSFQ -14 subscales 5 dimensions (pleasure, desire/frequency , 
desire/interest, arousal /erect ion, and orgasm/ejaculation) and 3 phases of the sexual response 
cycle (desire, arousal, and orgasm/co mpletion) at each visit assessed.
5.2.3 Additional Endpoints
Percentage of sub jects meet ing cr iteria for sexual dysfunct ion (ie, CSFQ -14 total score ≤47 for 
men and ≤41 for women) at any 2 consecutive visit s during the 5 -week double -blind Treatment 
Period.
Time to sexual dysfunct ion as assessed by the CSFQ -14.
Percentage of subjects with a shift in the CSFQ -14 from norm al (ie, CSFQ -14 total  score >47 
for men and >41 for women) at Baseline to abnormal (ie, CSFQ- 14 total score ≤47 for men and 
≤41 for wom en) at each visit assessed.
Percentage of subjects showing decreased sexual funct ion (ie, negative responders) according 
to the CSFQ -14 (ie, CSFQ -14 total  score decrease fro m Baseline ≥3) at each visit assessed.
Patient Gl obal Impressi on of Improvement (PGI -I) score at each visit assessed.
Columbia -Suicide Severit y Rating Scale (C -SSRS) at each visit assessed.
5.2.4 Safety Assessments
Safety and tol erabilit y will  also be evaluated using the following general assessments:
AEs.
Vital signs.
Clinical laboratory  tests.
Weight.
Physical examinat ions.
Vortioxetine
Study No. Vortioxetine -4001 Page 23of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL6.0 STUDY DESIGN AND DES CRIPTION
6.1 Study Design
This is a phase 4, mult icenter, randomized, double -blind, placebo -and active -controlled 
(paroxetine), 4 -arm, parallel group, fixed- dose study  com paring the effect of vortioxet ine (10 and 
20 m g QD) vs paroxetine (20 mg QD) on sexual funct ioning after 5 weeks of t reatment in healt hy 
adult men and wom en. This outpatient study  will be conducted at approximately 15 sites in North 
America. Men and wo men will be enrolled in approximately equal proportions (ie, 50% men and 
50% women, overall). Enro llment will be capped f or each sex when the enro llment target has been 
met for that sex stratum.
After providing informed consent, subjects will be assessed for study eligibilit y dur ing a Screening 
Period of  up to 4 weeks. Healthy  subjects who have norm al sexual  functioning (as defined by the 
CSFQ -14), have been in a steady  relationship for ≥3 months, are currently sexually active, and 
meet all other study  entry  criteria will be enrolled. At Baseline (Day 0), eligible subjects will be 
equally (1:1:1:1) randomized to double -blind vortioxetine 10 mg, vortioxetine 20 mg, paroxetine 
20 m g, or pl acebo and will be treated for 5 weeks. Randomization will be stratified by sex. 
Subjects allocated to vortioxet ine 20 mg will init iate treatment at 10 mg/day for the first week. 
Subsequently, the dose will be increased to 20 mg/day and remain at 20 mg/day unt il study  
completion. Subjects allocated to vortioxetine 10 mg will init iate treatm ent at 10 m g/day and 
remain at 10 mg/day unt il study co mpletion. Subjects allocated to paroxetine 20 mg will initiate 
treatm ent at 20 m g/day and rem ain at 20 mg/day unt il study  com pletion. Subjects will be 
instructed to take their first dose of study  drug the day  after Baseline on Day  1, preferably in the 
morning. After randomizat ion, subjects will be seen for w eekly visit s and receive a fo llow-up 
safet y contact 2 weeks after the end of double -blind treatment. At the end of 5 weeks of treatment, 
or at Early Terminat ion (ET), all subjects will abruptly  discontinue study  drug.
Sexual functioning will be assessed at each study visit using the CSFQ -14 (primary  variable). The 
PGI-I scale will be administered at each study visit  except at Screening and Baseline. Signs of  
suicidal risk will be assessed at each study  visit using the C -SSRS and the invest igator’s clinical 
judgment. Safet y will be assessed throughout the study . A total  of 6 sparse pharmacokinet ic (PK) 
samples (trough samples) will be collected to measure plasma vortioxet ine or paroxetine 
concentrations at Weeks 3, 4, and 5/ET (2 samples at each time point). A PGx blood sample for 
deoxy ribonucleic acid (DNA) iso lation will be collected at Baseline (Day  0), and 2 PGx blood 
samples for ribonucleic acid (RNA) iso lation will be co llected at Baseline (Day 0) and also at 
Week 5/ET (ie, 4 samples per subject).
The en d of the study  is defined as the date the last subject completes the Final Visit (Week 5).
A schemat ic of the study  design is presented in Figure 6.a. A schedule o f study  procedures i s 
provi ded in Appendix A.
Vortioxetine
Study No. Vortioxetine -4001 Page 24of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALFigure 6.a Schematic of Study Design
Note: The Follow -up Contact will be conducted by telephone.
6.2 Justification for Study Design, Dose, and Endpoints
6.2.1 Study Design
Healthy adult subjects were chosen for inclusio n in this study to eliminate the confounding effects 
on sexual function associated with psychiatric condit ions and certain medical condit ions. The 
durati on of  5 weeks was selected to allow for sufficient time to evaluate the extent of sexual 
dysfunct ion.
Paroxetine was chose n as an act ive co mparator as it is a co mmo nly prescribed SSRI and is known 
to cause sexual dysfunct ion, thereby allowing for validat ion of the study  (ie, the l evel of sexual 
dysfunct ion with paroxet ine is worse than that of placebo). The level o f sexual dy sfuncti on wi th 
vorti oxetine 10 and 20 mg will also be compared with placebo.
Since study  drug compliance is known to impact the study  resul ts, a com pliance techno logy 
vendor, Ai Cure, will be used to throughout the study to improve study  drug com pliance.
Inaddition, PK samples will be tak enat 3 postbaseline study  visits in order to assess plasma 
concentrations of vortioxet ine and paroxet ine. The compliance techno logy and/or PK 
concentration data will be used to define one or more modified full analysis set popul ations. 
6.2.2 Dose
Subjects will be dosed in accordance wit h the approved United States Package Insert for 
vorti oxetine; therefore, vortioxet ine doses of 10 and 20 mg will be evaluated. Based on 
prospective evaluat ion using the ASEX, the incidence o f TESD increased as the dose of 
vorti oxetine increases, although never statist ically different fro m placebo; therefore, the chosen Day 0
(Visit 2)Wk 5 
(Visit 7)Screening Baseline Screening Period
(up to 4 weeks)Double -Blind Treatment Period
(5 weeks)
Healthy SubjectsVortioxetine 10 mg/day
PlaceboVortioxetine 20 mg/day
Days -28 to -
1(Visit 1)EndpointParoxetine 20 mg/day
Wk 1
(Visit 3)Wk 2
(Visit 4)Wk 3
(Visit 5)Wk 4
(Visit 6)Vortioxetine
10 mg/day
Wk 7 
(Follow -up)Randomization
Vortioxetine
Study No. Vortioxetine -4001 Page 25of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALdoses of 10 and 20 mg for this study  are consi dered clinically  appropriate to eval uate sexual 
dysfunct ion as it includes the highes t therapeutic dose of vortioxet ine. 
A paroxet ine dose of 20 mg/day was selected as it is the starting dose and lowest effective dose for 
maintenance treatment for depression. Furthermore, this dose of paroxetine is considered to have 
the lowest incidence of TESD, but i t has also been shown to cause sexual dysfunct ion in healt hy 
subjects.
6.2.3 Endpoints
The CSFQ -14 is a validated questionnaire designed to assess and detect changes in sexual 
funct ioning (see Sect ion 9.1.8.1 ). In addit ion, it i s recogni zed by the Food and Drug 
Administrati on (FDA) as an accepted tool to assess sexual funct ioning in clinical studies.
The PGI -
I scale is a global self assessment used to rate th e response of a subject’s condit ion to 
therapy  or intervent ion (see Section 9.1.8.2 ). Although it was originally developed for assessment  
in wo men with stress urin ary incont inence, it has been used for subject self assessment in other 
condi tions due to i ts lack of specificit y to medical condit ions, and its sensit ivity to change. 
Adequate measures have been implemented in this study  to assess suicidal risk. The sele ction 
criteria exclude the participat ion of subjects at significant risk for suicide. Throughout the study , 
signs of  suicidal risk will be assessed both by  rating scal
e assessment (C -SSRS) and by 
investigator ’s clinical judgment. Subjects will be withdrawn from the study  in case of such risk. 
Furtherm ore, subj ects will be screened for the history  of suicidal behavio r.
6.3 Premature Termination or Suspension of Study or Study Sites
6.3.1 Criteria for Premature Termination or Suspension of the Study
The study  will be c ompleted as planned unless 1 or more of the fo llowing criteria are satisfied that 
requi re tem porary  suspensi on or early  terminat ion of the study .
New informat ion or other evaluat ion regarding the safet y or efficacy  of the study  drug that 
indicates a change in the known risk/benefit profile for the study  drug, such that the 
risk/benefit is no longer acceptable for subjects participat ing in the study .
Significant vio lation of Good Clinical Practice (GCP) that compromises the ability to achieve 
the primary  study objectives or compromises subject safet y.
6.3.2 Criteria for Premature Termination or Suspension of Study Sites
A study  site may  be terminated prematurely  or suspended if the site (including the invest igator) is 
found in significant vio lation of GCP, protocol , or contractual agreement, is unable to ensure 
adequate performance of the study , or as otherwise permitted by  the contractual  agreem ent.
Vortioxetine
Study No. Vortioxetine -4001 Page 26of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL6.3.3 Procedures for Premature Termination or Suspension of the Study or the 
Participation of Study Sites
In the event that the sponsor, an inst itutional review board (IRB), or regulatory  authori ty elects to 
terminate or suspend the study  or the parti cipat ion of a study  site, a study -specific procedure for 
early terminat ion or suspensio n will be provided by the sponsor; the pr ocedure will be fo llowed by 
applicable study  sites during the course of terminatio n or study  suspensi on.
Vortioxetine
Study No. Vortioxetine -4001 Page 27of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL7.0 SELECTION AND DISCONTINUATION/WITHDRAWAL OF SUBJECTS
All entry  criteria, including test results, need to be confirmed prior to randomizat ion. 
7.1 Inclusion Criteria
Subject eligibilit y is determined according to the following criteria prior to entry  into the study : 
1.In the opinion o f the invest igator, the subject is capable of understanding and complying wit h 
protocol  requi rements.
2.The subject signs and dates a wri tten, inform ed consent form  and any  requi red privacy 
authori zation prior to the init iation o f any study  procedures. 
3.The subject is a healt hy male or female aged 18 to 40 years, inclusive.
4.The subject has been in a steady  relati onship for ≥3months and plans to remain in that 
relationship for the duration of the study, and is current ly sexually active ( ≥2times per week) . 
Note: Partners are not allowed to enroll in this trial.
5.The subject has a body  mass index (BMI) of 18 to 35 kg/m2, inclus ive, at the Screening and 
Baseline Visits.
6.If female, the subject has a regular menstrual cycle (note: amenorrhea result ing fro m ho rmonal 
contraceptives is not exclusio nary).
7.A female subject of childbearing potential* who is sexually act ive with a nonster ilized* male 
partner agrees to routinely use adequate contraceptio n* fro m signing of informed consent 
throughout the duration of the study  and for 30 days after the last dose.
*Definit ions and acceptable methods of contraceptio n are defined in 
Secti on9.1.13 and reporting responsibilit ies are defined in Sect ion 9.1.14 .
8.The subject has normal sexual functioning, as defined by a CSFQ -14 total  score >47 (m en) or 
>41 (women) at the Screening and Baseline Visits.
9.If female, the subject taking allowed hormonal contraceptives is on a stable dose for ≥3months 
prior to the Baseline Visit and cont inues on the stable dose for the duration of the study. 
7.2 Exclusion Criteria
Any subject who meets any  of the fo llowing cri teria will not qualify  for entry  into the study :
1.The subject has received any invest igational co mpound within 30 days or 5 half-lives pri or to 
the Screening Visit, whichever is lo nger.
2.The subject has received vortioxet ine and/or paroxetine in a previous clinical study or as a 
therapeuti c agent.
3.The subject has previously  or is curr ently part icipating in this study .
Vortioxetine
Study No. Vortioxetine -4001 Page 28of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL4.The subject is an immediate family member, study site emplo yee, or i s in a dependent 
relationship with a study  site em ployee who i s involved in conduct of this study  (eg, spouse, 
parent, child, sibling) or may consent und er duress.
5. The subject has a clinically significant unstable illness, for example, hepatic impairment or 
renal insufficiency, or a cardiovascular, pulmonary, gastrointestinal, endocrine, neurological, 
rheumatol ogical, immunol ogical, hematol ogical , infecti ous, or dermatological disorder or 
metabo lic disturbance. Note: For the purposes of this study, gastric bypass surgery is 
considered to be an unstable condit ion due to the impact on medicat ion absorpti on.
6.The subject is positive for hepat itis B surface ant igen (HBsAg), ant i–hepat itis C virus (HCV) 
antibodies, or human immunodeficiency virus (HIV) at the Screening Visit or has any known 
sexually  transmi tted diseases.
7.The subject has 1 or more laboratory  value outsi de the norm al range, based on the blood or 
urine samples taken at the Screening or Baseline Visit, that are considered by the invest igator 
to be clinically significant; or the subject has any of the fo llowing values at the Screening or 
Baseline Visit:
a)A serum creat inine value >1.5× the upper limit s of normal (ULN).
b)A serum total bilirubin value >1.5×ULN.
c)A serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value 
>2×ULN.
8.The subject has glycosylated hemoglo bin (HbA1c) ≥7% at the Screening Visit.
9. The subject has a clinically signif icant abnorm al electrocardi ogram  (ECG) at the Screening 
Visit as determined by the central reader and confirmed as clinically significant by  the 
investigator. 
10.The subject has clinically significant abnormal vital signs at the Screening or Baseline Visit a s 
determined by the invest igator.
11.The subject has a known history  of or currently  has increased intraocul ar pressure or is at risk 
of acute narrow -angle glauco ma.
12.The subject has a history  of depressi on or any  other psy chiatri c illness including sleep 
disorders and prem enstrual  dysphori c disorder .
13.The subject has a significant risk of suicide according to the invest igator’s clinical judgment, 
or has made a suicide attempt at any  time.
14.The subject has current sexual dysfunct ion, or a history  of a diagnosis o r treatm ent of sexual 
dysfunct ion.
15.The subject has had a surgical or medical procedure on reproductive/genitourinary organs 
(excluding unco mplicated cesarean sect ion (C-sectio n), vasectomy, and tubal ligat ion that do 
not impact sexual funct ioning).
Vortioxetine
Study No. Vortioxetine -4001 Page 29of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL16.If fema le, the subject has polycyst ic ovarian syndrome.
17.The subject has hypogonadism or has a free testosterone value outside the normal range at the 
Screening Visit that is indicative of hypogonadism.
18.The subject has a thy roid-stimulat ing horm one (TSH) val ue out side the normal range at the 
Screening Visit that is deemed clinically significant by the invest igator. NOTE: Free thyroxine 
(T4) will be checked if TSH is out of range. If free T4 is abnormal the subject will be excluded.
19.The subject has a history  of hype rsensi tivity or allergi es to vorti oxetine or paroxetine or any  
associ ated excipients.
20. The subject is required to take ≥1 excluded medication or it is anticipated that the subject will 
be required to take ≥1 of the excluded medicat ions listed in Sect ion 7.3during the study.
21.The subject has a history  of or current al coho l or other substance abuse or dependence 
(according to Diagnostic and Statistical M anual  of Mental  Disorders, Fourth Edit ion, Text 
Revised [DSM -IV-TR] criteria).
22.The subject has habitual tobacco or other nicotine -containing product usage (equivalent to ≥10 
cigarettes per day ).
23.If female, the subject is pregnant or lactating or intending to becom e pregnant before, duri ng, 
or wi thin 30 days after participat ing in this study , or intending to donate ova during such time 
period. 
24.The subject is found to be a match in the subject registry  database wit h a subject who has 
participated in another study wit hin the last 30 days (or at any t ime for an excluded medical or 
psychiatric condit ion).
25.The subject has a disease or takes medication that, in the opinio n of the invest igator, could 
interfere wi th the assessments of sexual funct ioning, safet y, ortolerabili ty.
26.The subject, in the opinio n of the invest igator, is unlikely to comply wit h the clinical study  
protocol  or is unsuitable for any reason.
7.3 Excluded Medications and Treatments
A list of excluded medications and treatments is provided in
 Table 7.a. Use of the excluded 
medicat ions or treatm ents is prohibited fro m the time po ints specified until co mpletion of all study 
procedures at the Final V isit/ET Vi sit, unless approved by  the invest igator and Takeda on a 
case-by-case basis. 
Vortioxetine
Study No. Vortioxetine -4001 Page 30of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALTable 7.a Excluded Medications and Treatments
Drug ClassDisallowed Prior to/From
Baseline and
During Study Unless
Otherwise NotedDisallowed (X) During the Study 
[Sections Without (X) Indicate no Restriction]
Chronic
UseEpisodic
Use Comments or Exceptions
Any investigational drug <30 days before Screening or 
5half-lives, whichever is 
longerX X
Analgesics Narcotic 
analgesics3 months X X
NSAIDs X Up to 2 doses of ibuprofen or naproxen 
per week allowed. 
Aspirin is NOT allowed.
Cox-2 selective 
inhibitors3 months X X
Acetaminophen
Anorexics 2 weeks X X
Antacids
Antiacne agents
Antianginal agents 3 months X X
Antiarrhythmics 3 months X X
Antibiotics Rifampin is NOT allowed.
Antithrombic and 
anticoagulant agents 3 months X X
Anticonvulsants 3 months X X
Antidepressants (including 
MAOIs and RIMAs)3 months X X
Antidiarrheal agents
Antifungal agents 
Antihistamines X X Only loratadine, desloratadine, cetirizine, 
levocetirizine, mizolastine and 
fexofenadine are allowed.
Antihypertensives 3 months X X
Anti-impotence agents 3 months X X
Antimigraine agents 
(including triptans and 
dopamine antagonists)2 weeks X X
Antinauseants, antiemetics 
(including dopamine 
antagonists)2 weeks X X Only phosphoric acid and bismuth 
preparations are allowed.
Antineoplastics 3 months X X
Antiobesity agents 2 weeks X X
Antipsoriatic agents
Antimalarial 
Antipsychotics 3 months (6 months for depot) X X
Antivirals
Footnotes are on last table page.
Vortioxetine
Study No. Vortioxetine -4001 Page 31of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALTable 7.a Excluded Medications and Treatments (continued)
Drug ClassDisallowed Prior 
to/From
Baseline and
During Study Unless
Otherwise NotedDisallowed (X) During the Study 
[Sections Without (X) Indicate no Restriction]
Chronic
UseEpisodic
Use Comments or Exceptions
Anxiolytics (including 
benzodiazepines)3 months X X
Beta blockers 3 months X X
Cough/cold agents X Episodic treatment for up to 1 week is 
allowed.
Diuretics OTC
Herbal remedies, which are 
psychoactive (eg, St. Johns Wort, 
kava kava, valerian, and ginkgo 
biloba)2 weeks X X Melatonin is allowed.
Drugs metabolized by or that 
inhibit CYP2D62 weeks X X Applies to CYP2D6 
substrates/inhibitors not mentioned 
elsewhere in this table.
H2 blockers, proton pump 
inhibitors
Hormones X X Chronic and stable thyroid hormone 
replacement, parathyroid hormone, and 
its recombinant form (Forteo), 
contraceptives (oral, patch, injectables, 
and implants). 
Hypoglycemic agents 3 months X X
Hypolipidemics 3 months X X
Insulin 3 months X X
Laxatives
Mood stabilizers 3 months X X
Psychotropic agents not otherwise 
specified (including stimulants, 
narcotics, tryptophan, and 
dopamine agonists/antagonists)3 months X X
Sedatives/hypnotics 4 weeks
(see comments)X From 4 weeks prior to Baseline through 
end of study, only zolpidem, 
eszopiclone/zopiclone, zaleplon, and 
ramelteon allowed up to 2 nights per 
week and not the night before a study 
visit.
Footnotes are on last table page.
Vortioxetine
Study No. Vortioxetine -4001 Page 32of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALTable 7.a Excluded Medications and Treatments (continue d)
Drug ClassDisallowed Prior 
to/From
Baseline and 
During Study Unless
Otherwise NotedDisallowed (X) During the Study 
[Sections Without (X) Indicate no Restriction]
Chronic
UseEpisodic
Use Comments or Exceptions
Steroids: Systemic 2 weeks X X Injectable and anabolic steroids are also 
NOT allowed
Inhalant
Topical
Vaccines
COX -2=cyclooxygenase -2, CYP=cytochrome P450, H2 blockers=H2 receptor antagonists (acid reducers), MAOI=monoamine 
oxidase inhibitor, NSAID=nonsteroidal anti-inflammatory drug, OTC=over the counter , RIMA=reversible inhibitor of monoamine 
oxidase type A .
The list above does not include all o f the excluded medicat ions or supplements. Subj ects m ust be 
instructed not to take any  medicat ions or supplements, inc luding OTC products, throughout the 
durati on of  the study  without fi rst consul ting wit h the invest igator.
7.4 Criteria for Discontinuation or Withdrawal of a Subject
The primary  reason for di scont inuat ion or wi thdrawal  of the subject from  the study  or study drug 
shoul d be recorded in the electronic case report form (eCRF) using the following categories. For 
screen failure subjects, refer to Section 9.1.17 .
1.Pretreatment event (PTE) or AE. The subject has experienced a PTE or AE that requires ET 
because cont inued participat ion imposes an unacceptable risk to the subject’s health or the 
subject is unwilling to continue because of the PTE or AE.
Liver Funct ion Test (LFT) Abnormalit ies
Study  drug shoul d be discontinued immediately with appropriate clinical fo llow-up 
(including repeat laboratory  tests, until a subject’s laboratory  profile has returned to 
norm al/baseline status, see Section 9.1.12 ), if the following circumstances occur at any 
time during study  drug treatm ent:
–ALT or AST >8×ULN, or
–ALT or AST >5×ULN and persists for >2 weeks, or
–ALT or AST >3×U LN in conjunct ion with elevated total bilirubin >2×ULN or 
internat ional norm alized rati o (INR) >1.5, or
–ALT or AST >3×ULN with appearance of fat igue, nausea, vomit ing, ri ght upper 
quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%).
2.Signifi cant protocol deviat ion. The discovery postrando mizat ion that the subject failed to meet  
protocol  entry  criteria or di d not adhere to protocol requirements, and continued participation 
poses an unacceptable risk to the subject’s health.
Vortioxetine
Study No. Vortioxetine -4001 Page 33of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL3.Lost to follow -up. The subject did not return to the clinic and attempts to contact the subject 
were unsuccessful. Attempts to contact the subject must be documented in the subject’s source 
docum ents.
4.Voluntary  withdrawal. The subject wishes to withdraw from the study . The reason for 
withdrawal , if provi ded, shoul d be recorded in the eCRF.
Note: All attempts should be made to determine the underlying reason for the withdrawal and, 
where possible, the primary  underlying reason should be recorded (ie, withdrawal due to an 
AE s hould not be recorded in the “voluntary  withdrawal ” category ).
5.Study  terminat ion. The sponsor, IRB, or regulatory agency terminates the study.
6.Pregnancy. The subject is found to be pregnant.
Note: If the subject is found to be pregnant, the subject must be withdrawn immediately. The 
procedure is described in Sect ion 9.1.14 .
7.Noncom pliance wi th study  drug. This includes subjects who did not take the stu dy drug for 
≥4consecut ive days and/or are <70% compliant between visits.
8.Other.
Note: The specific reasons should be recorded in the “specify” field of the eCRF.
7.5 Procedures for Discontinuation or Withdrawal of a Subject
The invest igator may discont inue a subject’s study participat ion at any t ime during the study when 
the subject meets the study termination criteria described in Section 7.4. In addit ion, a subject may 
discontinue his or her participat ion without giving a reason at any  time during the study . Shoul d a 
subject’s participat ion be di scontinued, the primary  criterion for terminat ion must be recorded by  
the invest igator. In addit ion, efforts shoul d be made to perform all procedures scheduled for the ET 
Visit. Discont inued or withdrawn subjects will not be replaced. Discontinued or withdrawn 
subjects will receive a Fo llow
-up Contact.
Vortioxetine
Study No. Vortioxetine -4001 Page 34of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL8.0 CLINICAL STUDY MATER IAL MAN AGEMENT
This sect ion contains informat ion regarding all medicat ion and m aterials provi ded di rectly by the 
sponsor, and/or sourced by  other m eans, that are requi red by the study  protocol , including 
important sections describing the management of study  material.
8.1 Study Drug and Materials
8.1.1 Dosage Form, Manufacturing, Packaging, and Labeling
In thi s protocol , the term  study  drug refers to all or any  of the drugs defined below.
Commercial vortioxet ine tablets in encapsulated strengths of 10 and 20 mg .
Commercial paroxetine tablets in encapsulated strength of 20 mg.
Matching placebo capsules.
Vorti oxetine 10 and 20 mg tablets are manufactured by  Takeda or H. Lundbeck A/S, Valby, 
Denmark. Overencapsulat ion of the vortioxetine and paroxetine tablets and manufacturing of the 
matching placebo capsules (Swedish -Orange capsul es wi th lactose m onohydrate filler) is 
perform ed by  Almac Clinical Services, Souderton, PA, USA.
The study drug will be packaged in high -densit y polyethylene bottles wit h child-resistant closures. 
Each bottl e contains 7 daily doses plus 3 extra capsules for a total of 10 capsules per bottle. The 
daily  dose is 1 capsule by oral administration.
Bottl es of overencapsulated (OE) vortioxetine 10 and 20 mg tablets, OE paroxetine 20 mg tablets, 
and matching p lacebo capsules will be labeled wit h a single label and dispensed as double -blind 
for the 5 -week treatment phase. The study  drug will be ident ifiable by a unique medicat ion 
ident ificat ion (ID) number that will be assigned by an interactive web response sys tem (IWRS). 
Each bottle will be labeled with pert inent study information.
8.1.1.1 Study Drug
Vorti oxetine is a novel co mpound developed by Takeda and H. Lundbeck A/S as an antidepressant 
and treatment for MDD. Vortioxet ine belo ngs to a new chemical class of psycho tropi cs, the 
bis-aryl-sulfanyl amines, which possess unique properties co mpared with current ly known 
psychotropics. This new class of co mpounds is structurally different fro m all currently known 
psychotropics.
Vorti oxetine is commercially  formulated as imm ediate -release tabl ets intended for oral 
administration. The study  drug i s film -coated tabl ets containing the hydrobromide (HBr) salt of 
vorti oxetine. The tablets contain vortioxet ine-HBr corresponding to 10 and 20 mg o f vorti oxetine 
base. Well known excip ients are used to manufacture the tablet cores.
Paroxetine 20 mg tablets United States Pharmacopeia (USP) immediate release are commercially 
available. 
Vortioxetine
Study No. Vortioxetine -4001 Page 35of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL8.1.1.2 Sponsor -Supplied Drug
Sponsor -supplied drugs referenced in other sections of the protocol include the f ollowing :
Commercial vortioxet ine tablets in encapsulated strengths of 10 and 20 mg.
Commercial paroxetine tablets in encapsulated strength of 20 mg.
Matching placebo capsules.
8.1.2 Storage
Study  drug shoul d be stored at 25ºC (77ºF) with excursions permitted be tween 15ºC and 30ºC 
(59ºF -86ºF).
Vorti oxetine 10 and 20 mg, paroxetine 20 mg, and matching placebo must be kept in an 
appropriate, limited -access, secure pl ace until used or returned to the sponsor or designee for 
destruction. Vorti oxetine 10 and 20 mg, paroxetine 20 mg, and matching placebo must be stored 
under the condit ions specified on the label, and remain in the original container unt il dispensed. A 
daily  temperature l og of  the drug storage area must be maintained at the site every  working day .
8.1.3 Dose and Regimen
The invest igator or designee should contact the IWRS to register each subject at the init ial 
Screening Visit. At each applicable study  visit (Visi ts 1-5), the investigator or designee should 
contact the IWRS to receive the appropriate study  drug assignment for dispensation. The IWRS 
will provide the medicat ion ID number for each bottle dispensed at each study  visit. The 
medicat ion ID number assigned should be recorded in the source document.
Subjects assigned to vortioxetine 20 mg will init iate treatment at 10 mg/day for the first week. 
Subsequently, the dose will be increased to 20 mg/day  and rem ain at 20 mg/day unt il study  
completion. Subjects assigned to vortioxetine 10 mg will init iate treatment at 10 mg/day and 
remain at 10 m g/day unt il stud y completion.Subjects assigned to paroxetine 20mg will init iate 
treatm ent at 20 m g/day and rem ain at 20 m g/day  until  study  com pletion.
Subjects will be instructed to take 1 capsule per day, orally, at the same t ime of day, preferably in 
the morning, or a s directed. The first dose is to be taken on Day 1, the day after the study drug has 
been dispensed to the subject. Study drug can be taken wit h or without food. The subject should be 
advised to be consistent in the dosing time throughout the duration of t he study.
The invest igator or designee will instruct the subject on the dosing procedures and study drug 
storage requirements. Subjects should return their unused study  drug at each study  visit to all ow 
the invest igator or designee to evaluate subjects’ co mpliance wit h the dosing instructions.
The daily dose and capsule count that will be provided to each treatment group is described in 
Table 8.a. 
Vortioxetine
Study No. Vortioxetine -4001 Page 36of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALTable 8.a Dose and Regimen
Treatment Group Dose Treatment Description
A Placebo QD 1 placebo capsule
B 10 mg vortioxetine QD 1 OE vortioxetine 10 mg tablet 
C 20 mg vortioxetine QD 1 OE vortioxetine 20 mg tablet
D 20 mg paroxetine QD 1 OE paroxetine 20 mg tablet
8.1.4 Overdose
An overdose is defined as a known deliberate or accidental administration of study drug, to or by a 
study  subject, at a dose above that which is assigned to that individual subject according to the 
study protocol .
All cases of overdose (with or without associated AEs) will be documented on an Overdose page 
of the eCRF, in order to capture this important safety  information consistent ly in the database. 
Cases of overdose without manifested signs or symptom s are not considered AEs. AEs associated 
with an o verdose will be documented on an AE page of the eCRF, as described in Sect ion 10.1.5.3 .
Serious adverse events (SA Es) associ ated wi th overdose shoul d be reported accordi ng to the 
procedure outlined in Sect ion 10.2.2 .
In the event of drug overdose, general sympt omatic and supportive measures should be used, along 
with immediate gastric lavage where appropriate. Intravenous fluids should be administered as 
needed. As in all cases of drug overdose, respirat ion, pul se, bl ood pressure, and other appropriate 
signs sho uld be m onitored and general  supportive measures employed. 
As wi th the m anagement of all overdoses, the possibilit y of multiple drug ingest ion should be 
considered. The physician may contact a poison control center for current information on the 
managemen t of overdose. 
8.2 Study Drug Assignment and Dispensing Procedures
The invest igator or invest igator’s designee will access the IWRS at the Screening Visit to obtain 
the subject number . The investigator or investigator’s designee will access the IWRS to random ize 
the subject into the study shoul d they  meet the eligibilit y requi rements. Subjects will be assigned 
in a 1:1:1:1 ratio to 1of the 4 treatment arms of vortio xetine 10 mg, vortioxet ine 20 mg, paroxetine 
20 m g, or pl acebo. Randomization will be stratifie d by sex. Men and women will be enrolled in 
equal  proporti ons (ie, 50% men and 50% women, overall). Enrollment will be capped for each sex 
when the enrollment target has been met for that sex stratum.
During each IWRS contact, the invest igator or designee will provide the necessary  
subject -ident ifying informat ion, including the subject number assigned at Screening. The 
medicat ion ID number of the study  drug to be di spensed will then be provided by the IWRS. If 
sponsor -supplied drug is lost or damaged, the site can request a replacement fro m the IWRS (refer 
to IWRS m anual provi ded separately). At subsequent drug -dispensing visit s, the invest igator or 
Vortioxetine
Study No. Vortioxetine -4001 Page 37of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALdesignee will again contact the IWRS to request addit ional study  drug for a subject. The 
medicat ion ID number of the study drug to be di spensed will be provided by the IWRS.
Each subject should be instructed as follows:
The subject should keep sponsor -supplied drugs in original containers unt il the time of dosing.
The subject should take only  1 capsule per day  as instructed. If the dose is missed in the 
morning, it is acceptable to take the dose later in the same day. If the subject misses a dose, he 
or she should not take twice the dose the next day . 
The subject s hould store sponsor -supplied drugs according to the label and keep them out of 
the reach of children.
The subject is to return sponsor -supplied drugs at each study visit.
8.3 Randomization Code Creation and Storage
Takeda randomization personnel or designee wi ll generate the randomizat ion schedule for the 
study; an IWRS will be used in a centralized fashion for subject randomizat ion and study  drug 
assignments with stratificat ion by sex. All rando mization informat ion will be stored in a secured 
area, accessible only by authorized personnel. Target rando mizat ion is 50% men and 50% women; 
enrollment for each sex will be monitored and will be discontinued once the appropriate numbers 
of subjects have been enrolled for a sex stratum.
Subjects will be assigned in a 1:1:1:1 ratio, within each sex stratum, to the 4 treatment arms of 
vorti oxetine 10 mg, vortioxet ine 20 mg, paroxetine 20 mg, or placebo. Subject randomizat ion 
across treatments and sex will be balanced at the study  level.
8.4 Study Drug Blind Maintenance
The s tudy drug blind will be maintained using the IWRS. The principal invest igator at each study 
site will  receive instructi ons for ob taining the study  drug assignment through the IWRS. During 
regul arly scheduled monitoring visits, a study mo nitor from the spon sor or a designee will perform 
an inventory of assigned and unassigned bottles of study drug. All assigned/unassigned study drug 
bottles will  be reconciled and returned to the sponsor or a designee before study  closure.
8.5 Unblinding Procedure
The study  drug blind shall not be broken by the investigator unless informat ion concerning the 
study  drug i s necessary for the medical treatment of the subject. If possible, the sponsor/designee 
shoul d be notified before the study  drug blind is broken. If a medical emerg ency requiring 
unblinding occurs, the investigator (or designee) at the site will contact the sponsor or designee 
(see medical mo nitor contact information listed in Section 1.1) to assess the necessit y to break the 
study  drug blind.
For unblinding a subject, the study
 drug blind can be obtained by accessing the IWRS. The 
sponsor/designee must be notified immediately if the study  drug blind is broken. The date, time, 
Vortioxetine
Study No. Vortioxetine -4001 Page 38of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALand reason the blind was broken must be recorded in the source documents and on the appropriate 
eCRF.
If any site personnel is unblinded, study drug must be stopped immediately and the subject must be 
withdrawn from the study. The reason for withdrawal sho uld be recorded as “Protocol Deviat ion.”
8.6 Accountability and Destruction of Sponsor- Supplied Drugs
Drug supplies will be counted and reconciled at the site before being returned to the sponsor or 
designee.
The investigator or designee must ensure that the sponsor -supplied drug is used in accordance wit h 
the protocol and is dispensed only to subjects enro lled in the study . To docum ent appropri ate use 
of sponsor -supplied drug (vortioxetine 10 and 20 mg, paroxetine 20 mg, and placebo), the 
investigator or desig nee m ust m aintain records of all sponsor -supplied drug delivery  to the si te, 
site inventory , dispensation and use by  each subject, and return to the sponsor or designee.
Upon receipt of sponsor -supplied drug, the invest igator or designee must verify the co ntents of the 
shipments against the packing list. The verifier should ensure that the quantit y is correct, and the 
medicat ion is in good condit ion. If quant ity and condit ions are acceptable, the invest igator or 
designee should acknowledge the receipt of th e shipm ent by  recording in the IWRS. If there are 
any discrepancies between the packing list vs the actual product received, Takeda must be 
contacted to resolve the issue. The packing list should be filed in the investigator’s essent ial 
docum ent file.
The invest igator or designee must maintain 100% accountabilit y for all sponsor -supplied drugs 
received and dispensed during his or her entire participat ion in the study . Proper drug 
accountabilit y includes, but is not limit ed to the following:
Frequent ly verif ying that actual inventory  matches docum ented inventory .
Verifying that the log is completed for the drug lot (or medication ID number) used to prepare 
each dose.
Verifying that all containers used are documented accurately on the log.
Verifying that requi red fields are com pleted accurately  and legibly .
If any dispensing errors or discrepancies are discovered, the sponsor must be notified immediately.
The IWRS will include all required informat ion as a separate entry  for each subject to whom 
sponsor -supplied drug is di spensed.
The invest igator or designee must record the current inventory of all sponsor -supplied drugs
(vorti oxetine 10 and 20 mg, paroxetine 20 mg, and placebo) on a sponsor -approved drug 
accountabilit y log. The fo llowing informat ion will be re corded at a minimum: protocol number 
and tit le, name of invest igator, site ident ifier and number, descript ion of sponsor -supplied drugs, 
expiry  and/or retest date, date and amount dispensed including initials, seal, or signature of the 
person di spensing th e drug, and the date and amount returned to the site by  the subject, including 
Vortioxetine
Study No. Vortioxetine -4001 Page 39of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALthe init ials, seal, or signature of the person receiving the sponsor -supplied drug. The log should 
include all required informat ion as a separate entry for each subject to whom sponsor -supplied 
drug i s dispensed. 
All study  drug not returned to the site by a subject must be invest igated by the site and 
appropriately  docum ented on the drug accoun tability  log.
Prior to si te closure or at appropriate intervals, a representative from the sponsor or its designee 
will perform sponsor -supplied drug accountabilit y and reconciliat ion before sponsor -supplied 
drugs are returned to the sponsor or its designee for destruct ion. The invest igator or designee will 
retain a copy  of the docum entati on regarding sponsor -supplied drug accountabilit y, return, and/or 
destruction, and originals will be sent to the sponsor or designee.
In the event of expiry date extensio n of sponsor -supplied drug already  at the study  site, 
sponsor -supplied drugs may be relabeled with the new expiry  date at that si te. In such cases, 
Takeda or i ts desi gnee will  prepare addi tional labels, certificates of analyses, and all necessary  
docum entati on for com pletion of  the procedure at the sites. 
Vortioxetine
Study No. Vortioxetine -4001 Page 40of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL9.0 STUDY PLAN
9.1 Study Procedures
The fo llowing sections describe the study procedures to be performed and data to be collected. For 
each procedure, subjects are to be assessed by the same invest igator or site personnel whene ver 
possible. The Schedule of Study  Procedures i s located i n Appendix A.
9.1.1 Informed Consent Procedure
The requirements of the informed consent are describ ed in Sect ion
 15.2. Informed consent must be 
obtained prior to the subject entering into the study, and before any protocol -directed procedures 
are p erform ed. 
PGx informed consent is a component of the overall study  inform ed consent. Collect ion of PGx 
blood sam ples is mandatory  for each subject (see Section
 9.1.15 ).
The Subject Database Authorizat ion will also be a component of the overall study  informed 
consent (see Section
 9.1.2 ).
A unique subject ID number (subject n umber) will be assigned to each subject at the time that 
inform ed consent i s obtained; this subject number will be used throughout the study .
9.1.2 Subject Database and Authorization
Clinical trial subject registries seek to reduce subjects from enrolling into m ultiple clinical trials by 
ident ifying duplicates before enro llment. This study will ut ilize one or more subject registry 
databases. At the time of providing the informed consent for the study, the invest igator or designee 
will explain to the subject the I RB-approved Subject Database Authorizat ion and witness the 
signature.
During Screening, site staff who have received training and login informat ion to access the registry 
will enter the subject study  ID and authori zed subject i dentifiers. An immediate repo rt detailing 
matches is generated and should be printed for source documentation. The report will specify 
either (1) no m atches found, (2) a match was found with a subject participating in another study  
within 30 days, or (3) the subject matches with a sub ject who has prescreened/screened at another 
site. 
9.1.3 Demographics, Medical History, Psychiatric History, and Medication History 
Procedure
Dem ographic information to be obtained will include date of birth, sex, Hispanic ethnicit y, race as 
described by the su bject, and smoking status of the subject at Screening. 
Medical history  and psychiatric history  to be ob tained will include determining whether the 
subject has any significant conditions or diseases relevant to the disease under study that stopped at 
or pr ior to si gning o f informed consent. Ongoing medical and/or psychiatric condit ions are 
considered concurrent condit ions (see Section 9.1.11 ).
Vortioxetine
Study No. Vortioxetine -4001 Page 41of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALMedicat ion history  informat ion to be obtained includes any medicat ion relevant to eligibilit y 
criteria and the efficacy/safet y evaluati on stopped at or within 90 days prior to signing of informed 
consent.
9.1.4 Physical Examination Procedure
A baseline physical examinat ion (defined as the assessment prior to first dose of study  drug) will 
consist of the fo llowing body  systems: (1) ey es; (2) ears, nose, throat; (3) cardiovascular system; 
(4) respi ratory  system; (5) gastrointestinal system; (6) dermatologic system; (7)extremit ies; (8) 
musculoskeletal system; (9) nervous system; (10) lymph nodes; and (11) other. A genitourinary  
examinat ion will not be required. 
All subsequent phy sical examinat ions shoul d assess clinically  significant changes from  the 
assessment pri or to the first dose of study  drug (baseline examinat ion).
9.1.5 Weight, Height, and BMI
A subject should have weight and height measured while wearing indoor clothing and with shoes 
off. The Takeda standard for collect ing height is cent imeters without decimal p laces and for 
weight it is kilograms (kg) with 1 decimal place. BMI should be derived as fo llows: 
BMI = weight (kg)/[hei ght (m )]2
Note that although height is measured in centimeters, the BMI formula uses meters for height; 
meters can be determined by  dividing centimeters by 100. Thus, for example, if height=176 cm 
(1.76 m eters) and wei ght=79.2 kg, then BMI=79.2/1.762=25.56818 kg/m2.
BMI values will be reported to 1 decimal place by rounding. The above value should be captured 
as 25.6 kg/m2in the database .
9.1.6 Vital Sign Procedure
Vital signs will  include body  temperature (oral  or tympanic), pulse (beats per minute), and sitting
blood pressure (taken after 5 minutes in the sitting posit ion).
When vital signs are scheduled at the same t ime as blood draws, the blo od draw will take priorit y 
and vital signs will be obtained before or after the scheduled blood draw.
9.1.7 ECG Procedure
A standard 12- lead ECG will be recorded. The fo llowing parameters will be recorded 
electroni cally  by a central reader from the subject’s ECG trace: heart rate, RR interval, PR interval, 
QT interval, QRS interval and corrected QT interval. The central reade r will  interpret the ECG 
using 1 of the fo llowing categori es: wi thin norm al limits or abnorm al. If  interpreted as abnormal, 
the invest igator will assess the findings as either abnormal clinically significant, or abnormal not 
clinically significant. The int erpretation of the ECG will be recorded in the source documents and 
in the eCRF. ECG traces recorded on thermal paper will be photocopied to avoid degradat ion of 
Vortioxetine
Study No. Vortioxetine -4001 Page 42of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALtrace over time. Requirements for the ECG equipment and procedure for collect ing and 
transferr ing informat ion to the central reader will be provided in the site manual. 
9.1.8 Sexual Functioning Assessments
9.1.8.1 CSFQ -14
The CSFQ -14 is a structured self -reported questi onnaire designed to measure illness -and
medicat ion-related changes in sexual funct ioning tha t consists of 14 i tems measuring sexual
funct ioning as a total score (14 items) and on the subscales o f pleasure (1 i tem), desi re/frequency
(2 items), desi re/interest (3 i tems), arousal  (3 items), and orgasm (3 items). Two addit ional items
are included in the total  score, but do not map to a specific phase of the sexual response cycle.
Lower scores are associated with worsened sexual funct ioning [20]. The subject should complete 
the CSFQ- 14 scale before the PGI -I scale at all post -baseline visits .
9.1.8.2 PGI-I Scale
The PGI -I scale is a global self assessment used to rate the response of a subject’s condit ion to 
therapy  orintervent ion. It consists of one question that asks the subject to rate their current 
condi tion compared to how it was prior to beginning treatm ent on a scale of 1 (very much better) to 
7 (very  much worse). It was originally  devel oped for assessment in wo men with stress urinary  
incont inence [21]. However, due to its lack o f specificit y for medical condit ions, and its sensit ivity 
to change, it has been used for subject self assessment in other condit ions. The subje ct shoul d 
complete the CSFQ -14 scale before the PGI -I scale at all post -baseline visit s.
9.1.9 C-SSRS
The C -SSRS was developed by researchers at Columbia Universit y as a t ool to help systemat ically 
assess suicidal ideat ion and behavior in subjects during participat ion in a clinical study of 
centrally -acting drugs [22,23]. The C -SSRS i s composed of 3 questions addressing suicidal 
behavior and 5 questions addressing suicidal ideat ion, with subquest ions assessing the severit y. 
The tool  is administered via interview with the subject.
9.1.10 Documentation of Concomitant Medications
Concomitant medicat ion is any drug given in addit ion to study drug. These may be prescribed by a 
physician or obtained by the subject over the coun ter. Concomitant medicat ion is not provi ded by 
Takeda. At each study  visit, subjects will be asked whether they  have taken any  medicati on other 
than study  drug (used from signing of informed consent through the end of the study ), and all  
medicat ion including vitamin supplements, over -the-counter medicatio ns, and oral herbal 
preparati ons, m ust be recorded in the eCRF.
9.1.11 Documentation of Concurrent Medical and/or Psychiatric Conditions
Concurrent medical and/or psy chiatric condit ions are those significant ongoing condit ions or 
diseases that are present at signing of informed consent. This includes clinically  significant 
Vortioxetine
Study No. Vortioxetine -4001 Page 43of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALlaboratory , ECG, or phy sical examinat ion abnormalit ies noted at the screening or baseline 
examinat ion. The condit ion (ie,diagnosis) shoul d be described.
9.1.12 Procedures for Clinical Laboratory Sampl es 
Laboratory  samples will be collected at the time points stipulated in the Schedule of Study  
Procedures ( Appendix A). The m aximum  volume of  blood coll ected at any  single visit is 
approximately  25 mL, and the approximate total volume of blood for the study  is 88 mL 
(Table 9.a). Samples will be collect ed in accordance with acceptable laboratory  procedures.
Details o f these procedures and required safet y monitoring will be given in the laboratory manual. 
Table 9.a Approximate Blood Volume
Sample TypeVolume
per
SampleNumber of Samples (a)
Total 
VolumeScreening
Period BaselineTreatment
PeriodFinal Visit/
ET Visit
HBsAg, HCV, HIV 6 mL 1 --- --- --- 6 mL
Free testosterone, 
TSH/free T4, HbA1c2 mL 3 (b) --- --- --- 6 mL
Serum chemistry tests (c) 6 mL 1 1 --- 1 18 mL
Hematology tests 2 mL 1 1 --- 1 6 mL
PK analysis (d) 6 mL --- --- 4 2 36 mL
DNA isolation 6 mL --- 1 --- --- 6 mL
RNA isolation 2.5 mL --- 2 --- 2 10 mL
Total Blood Volume 88 mL
---=not applicable.
(a) Does not include blood draws at any unscheduled visits.
(b) One 2 mL blood sample for each test.
(c) Includes serum pregnancy test for women of childbearing potential.
(d) For measurement of vortioxetine or paroxetine concentrations in plasma.
The clinical laboratory  tests to be performed are listed in Table 9.b.
Vortioxetine
Study No. Vortioxetine -4001 Page 44of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALTable 9.b Clinical Laboratory Tests
Hematology Serum Chemistry Urinalysis
RBC s
WBC s
Hemoglobin
Hematocrit
Platelets 
Neutrophils
Eosinophils
Basophils
Lymphocy tes
Monocytes
HbA1c (a)ALT
Albumin
Alkaline phosphatase
AST
Total protein
Creatinine
Blood urea nitrogen
Creatine kinase
GGT
Potassium
Sodium
Total bilirubin
Direct bilirubin (b)
Calcium
Glucose (fasting or nonfasting)
INR ( d)
Lipids (fasting or nonfasting):
Triglycerides
Total cholesterol
High -density lipoprotein cholesterol (direct)
Low-density  lipoprotein cholesterol (Friedwald)Specific gravity
pH
Glucose
Protein
Occult blood 
Microscopic battery:
WBCs, RBCs, epithelial
cells, casts (c)
Other:
Serum Urine
HIV (a)
HBsAg (a)
HCV (a)
TSH, free T4 (e)
Free testosterone (a)Drug screen: anabolic steroids ,amphetamine, barbiturates, 
benzodiazepines, cannabinoids, cocaine metabolites, 
opiates, ethyl alcohol, methadone, phencyclidine, 
propoxyphene, methaqualone, and oxycodone (f)
Female subjects of childbearing potential Female subjects of childbearing potential
Beta hCG (for pregnancy) (a) Beta hCG (for pregnancy) (g)
GGT= -glutamyl transferase, hCG=human chorionic gonadotropin, RBC=red blood cell, WBC=white blood cell.
(a) To be performed at Screening only.
(b) To be performed only if total bilirubin ≥2 mg/dL. 
(c) Microscopic examination of sediment to be performed only if the dipstick results are positive .
(d) To be performed only if subjects experience ALT or AST >3×ULN as part of the required follow -up la boratory 
tests.
(e) TSH to be measured at Screening to exclude subjects with clinically significant thyroid dysfunction 
(hyperthy roidism o r hypothy roidism), which may impact sexual functioning. If TSH value is outside the normal 
range, free T4 will be meas ured.
(f) To be performed at Screening, Baseline, and at any time at the discretion of the investigator.
(g) To be performed at all study visits except Screening.
The central laboratory  will perform  all clinical laboratory  tests wi th the except ion of the urine 
pregnancy (hCG) tests, which will be performed at the study site .The clinical laboratory  test 
resul ts will  be returned to the investigator, who will be responsible for filing and reviewing these 
Vortioxetine
Study No. Vortioxetine -4001 Page 45of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALresul ts together wi th the data in the eCRF. The investi gator i s responsible for recording the 
interpretati on of  clinical significance of any  abnormal  laboratory  resul ts in the eCRF .The 
investigator will maintain a copy  of the l aboratory  accredi tation and the reference ranges for the 
laboratory  used.
If subjec ts experi ence ALT or AST >3×ULN, follo w-up laboratory  tests (at a minimum, serum 
alkaline phosphatase, ALT, AST, total bilirubin, GGT, and INR) should be performed wit hin a 
maximum o f 7 day s and preferably within 48 to 72 hours after the abnormalit y was no ted.
(Please refer to Section 7.4for discont inuat ion criteria, and Sect ion 10.1.5.2 for the appropriate 
guidance on reporting of abnorm al LFTs in relat ion to ALT or AST >3×ULN in conjunct ion with 
total bilirubin >2×ULN.)
If the ALT or AST remains elevated >3×ULN on these 2 consecut ive occasions the invest igator 
must contact the medical mo nitor for consi derat ion of addit ional testing, cl ose m onitoring, 
possible discont inuat ion of study  drug, and discussio n of the relevant subject details and possible 
alternat ive et io
logies. The abnormalit y should be recorded a s an AE (please refer to Section 10.2.3
for reporting requirements).
For subjects with posit ive drug screen results, confirmation testing should be performed ( except 
for ethyl  alcohol ).If methadone testing is to be performed after vortioxetine administration, 
confirmat ion testing must be performed as false posit ives may occur.
9.1.13 Contraception and Pregnancy Avoidance Procedure
From  signing of informed consent, through out the duration of the study , and for 30 days after last 
dose of study  drug, female subjects of childbearing potential* who are sexually  active wi th a 
nonsterilized male partner** must use adequate contraception. In addit ion they  must be advised 
not to do nate ova during this period.
*Females NOT of childbearing potential are defined as those who have been surgically sterilized 
(hysterectomy, bilateral oophorectomy or tubal ligation) or who are postmenopausal (eg, defined 
as ≥1 year since last regular menses with a fo llicle -stimulat ing hormone level >40 IU/L or ≥5 ye ars 
since l ast regul ar menses, confirmed before any  study  drug i s implemented).
**Sterilized males should be ≥1 year postvasectomy  and have confirmed that they  have obtained 
docum entati on of the absence of sperm in the ejaculate.
Vortioxetine
Study No. Vortioxetine -4001 Page 46of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAn acceptable method of contraception is defined as one that has no higher than a 1% failure rate. 
In thi s study , where medicat ions and devices containing hormones are included, the only 
acceptable methods of contra cepti on are as fo llows: 
Barrier methods (each time the 
subject has intercourse):Intrauterine devices 
(IUDs):Hormonal contraceptives:
Male condom PLUS spermicide.
Cap (pl us spermicidal cream or 
jelly) PLUS male condom and 
spermicide.
Diaphragm  (plus spermicidal 
cream  or jelly) PLUS male 
condom  and spermicide.Copper T PLUS condom 
or spermicide.
Progesterone T PLUS 
condom  or spermicide.Implants.
Horm one shot/i njecti on.
Combined pill.
Minipill.
Patch.
Vaginal ring PLUS male 
condom  and spermicide.
Subjects will be provided with information on acceptable methods of contraception as part of the 
subject informed consent process and will be asked to sign a consent form stating that they  
understand the requirements for avoidance of pregnancy and donation of ova during the course of 
the study .
During the course of the study , regular urine hCG pregnancy tests will be performed only  for 
wom en of childbearing potential and subjects will receive cont inued guidance with respect to the 
avoidance of pregnancy as part of the study  procedures ( Appendix A).
In addit ion to a negative serum hCG pregnancy test at Screening, subjects also must have a 
negat ive urine hCG preg nancy test at Baseline prior to receiving any dose of study drug.
9.1.14 Pregnancy
If any subject is found to be pregnant during the study  she shoul d be wi thdrawn and any 
sponsor -supplied drug (vortioxet ine, paroxetine, or placebo) should be immediately discont inued. 
If the pregnancy  occurs during administration of active study  drug, eg, after the Baseline Visit or 
within 30 days of the last dose of active study drug, the pregnancy should be reported immediately, 
using a pregnancy  notificat ion form, to the contac t listed in Section
 1.1.
Shoul d the pregnancy  occur during or after administration of blinded drug, the invest igator must 
inform  the subject of their right to receive treatment information. If the subject chooses to receive 
unblinded treatment informat ion, the individual blind should be broken by the invest igator. 
Subjects rando mized to placebo need not be fo llowed.
If the female subject agrees to the primary  care physician being informed, the invest igator should 
notify the primary  care physician that the subject was participat ing in a clinical study at the time 
she became pregnant and provide details of treatment the subject received (blinded or u nblinded, 
as applicable).
Vortioxetine
Study No. Vortioxetine -4001 Page 47of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAll pregnancies in subjects on active study drug, including comparator, will be followed up to fina l 
outcom e, using the pregnancy  form. Pregnancies will remain blinded to the study  team . The 
outcom e, including any  premature termin ation, must be reported to the sponsor. An evaluat ion 
after the bi rth of  the child will also be conducted.
9.1.15 PGx Sample Collection
DNA form s the basis for the genes that make the body  produce proteins such as enzymes, drug 
transporters, or drug targets, and may be evaluated for the genet ic contribut ion to how the drug is 
broken down or how the drug affects the body . This i s called a “PGx research study .” Specific 
purposes of such a study  include the fo llowing:
Identifying genet ic reasons why certain people respond differently to vortioxet ine.
Finding out more informat ion about how vortioxetine works.
Generat ing informat ion needed for research, development, and regulatory  approval  of tests to 
predi ct response to vortioxetine.
Ident ifying variations in genes r elated to the bio logical target of vortioxetine.
This information may be used, for example, to develop a better understanding of the safet y and 
efficacy of vortioxet ine and other study drugs, and for improving the efficiency, design, and study 
methods of f uture research studies.
In the current study, co llection of PGx blood samples is mandatory for each subject. PGx informed 
consent is a component of the overall study  informed consent. 
One 6 -mL who le blood sample for DNA iso lation will be co llected predos e at Baseline (Day 0) 
from each subject in the study , into pl astic potassium ethylenediamine tetraacetic acid (K 2EDTA) 
spray -coated tubes, and stored under frozen condit ions. If necessary and feasible, a second aliquot 
of blood m ay be co llected if iso lation of DNA fro m the first sample was not successful or possible. 
In addit ion, if the who le blood sample for DNA isolat ion is not collected at Baseline, it may be 
collected at any  point in the study .
Two 2.5 -mL who le blood samples for RNA iso lation will be co llected predose at Baseline (Day 0 ) 
and also at Week 5/ET from each subject in the study  (ie, 4 sam ples per subject), into a PaxGene 
tube. 
Each PGx sample for a study  subject shoul d be ident ifiable on the requisit ion form with a 8-digit 
subject ID number (the 5 -digit site number plus the 3 -digit subject number).
The samples will be stored for no longer than 15 years after complet ion of the vortioxet ine study . 
No sam ples will  be stored for l onger than permitted by  the applicable law and samples will be 
destroyed upon notificat ion from Takeda. “Stored samples” are defined as samples that are 
key-coded (the samples are stripped of all personal identifying information but a key  links the 
samples to the clinical data collected fro m the sampl e donor) and are used in the analysis of study 
drug or related drugs.
Vortioxetine
Study No. Vortioxetine -4001 Page 48of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALDetailed instructions for the handling and shipping of samples are provided in the study laboratory 
manual.
9.1.16 PK Sample Collection and Analysis
9.1.16.1 Collection of Plasma for PK Sampling
A total o f six 6 -mL PK blood samples (trough samples) will be co llected fro m each subject at 
3separate study  visits (2 sam ples at each time point at Weeks 3, 4, and 5/ET). At Week 5/ET, the 
blood sam ple will be collected at the same time point as the blood sample for clinical labora tory 
tests. Subj ects will be instructed to take the study  drug immediately after PK blood samples are 
collected. The exact date and time of last dose prior to the scheduled PK visit as recorded on the 
subject diary , the exact time of PK blood draws, and th e exact time of dose taken at the site at the 
PK visit will be recorded on the appropriate eCRF. 
Please refer to Appendix Efor instructions for the collect ion, handling, and shipping of plasma 
samples for PK analysis. Samples co llected fro m subjects in the vortioxetine and paroxet ine 
groups will be analyzed by  the bi oanaly tical laboratory  to m easure vorti oxetine and paroxetine 
concentrations in plasma , respectively. Samples collected fro m subjects in the placebo groups will 
not be analyzed. The bioanalyt ical laboratory  will be unblinded to select the subjects receiving 
vorti oxetine or paroxetine.
9.1.16.2 Bioanalytical Methods
Plasma concentrations o f vorti oxetine and paroxet ine will be measured by a validated 
high-performance liquid chromatography  with tandem  mass spectrometry  method.
9.1.17 Documentation of Screen Failure
Invest igators must account for all subjects who sign informed consent.
If the subject is found t o be not eligible at the Screening Visit, the invest igator should co mplete the 
eCRF. The IWRS should be contacted as a notification of screen failure. The primary  reason for 
screen failure is recorded in the eCRF using the fo llowing categories:
PTE/AE.
Didnot m eet incl usion criteria or di d meet exclusion criteria (specify  reason).
Significant protocol  deviat ion.
Lost to follow -up.
Voluntary  withdrawal (specify  reason).
Study  terminat ion.
Other (specify reason).
Subject numbers assigned to subjects who fail screening should not be reused.
Vortioxetine
Study No. Vortioxetine -4001 Page 49of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL9.1.18 Documentation of Rescreening
Rescreening of subjects who do not meet eligibilit y requirements i s not allowed. If the principal 
investigator believes in the appropriateness o f the subject for the study  and considers a re screen, 
permission for this must be obtained fro m the medical m onitor. Rescreening at the invest igator’s 
discreti on wi thout pri or approval fro m the medical m onitor is not permi tted.
9.1.19 Documentation of Study Entrance
Only subjects who meet all of the inclusio n criteria and none of the exclusio n criteria are eligible 
for entrance into the Treatment Period.
If the subject is found to be not eligible for the Treatment Period, the investigator should record the 
primary  reason for failure on the applicable eCRF.
9.2 Monitoring Subject Treatment Compliance
A digital com pliance techno logy will be implemented in this study , as described below. Subjects 
will also be required to bring study  drug con tainers to each clinic visit, regardless of whether the 
study  drug container is empt y.
Subjects will be mo nitored for com pliance using AiCure’s artificial intelligence plat form. The 
techno logy will be provi ded as a smartphone application. Subjects will use the smartphone 
applicat ion to m onitor them selves taking the study  drug. Subj ects will eit her download the 
applicat ion to thei r own sm artphone, or for subjects who do not have a smartphone or who do not 
wish to downl oad the applicat ion to thei r own device, a smartphone- like device will be issued to 
them and m ust be returned at the end of their participat ion in the study . The Heal th Insurance 
Portabilit y and Accountabilit y Act (HIPAA) –compliant artificial intelligence so ftware is able to 
ident ify and confirm the subject, the study  drug, and ingest ion of the study  drug. 
The subjects will mo nitor them selves taking the study  drug using the applicat ion each time they 
take the study drug during the study. At the required dosing t ime, the software provides a reminder 
and takes the subject through a mult istep process: (1) subject ident ification; (2) study drug 
ident ificat ion; (3) confirmat ion that the subject has placed the study drug in his or her mouth. After 
determinat ion of medication adherence by the smartphone application, d ata captured will be 
encrypted and transmitted to a secure, ce ntralized, web -based dashboard, which the study  site can 
access through a roles -and-rules-restri cted, HIPAA -compliant system . When a subject is init ially 
registered, a resi dential and/or m obile phone number will be encry pted and stored onto the 
dashboard. Subjects will also be able to manually enter into their device at a later time period if 
they took study drug but di d not have their device on them, or if it was not working at the time.
If the study  drug is not taken or is not taken correctly , the study  site will be notified through the 
dashboard as well as by email or short message service (SMS) messaging. Study sites will be able 
to intervene wit h the subject direct ly through the dashboard if the study drug is not taken or not 
taken correctly. In addit ion, subjects will receive an automated message to their device reminding 
them to take their study drug, or if there is a low battery. The device will ring if subjects are late in 
taking their study  drug. Subj ects will provide written consent to be contacted via SMS messaging 
Vortioxetine
Study No. Vortioxetine -4001 Page 50of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALin accordance with their use of the AiCure plat form, at the clinical site when agreeing to participate 
in the study . 
Subjects will be trained on how to use the application and will participate in a practice sessio n at 
the Baseline Visit . During the practice sessio n, subjects will be requested to take small pract ice 
pills to demonstrate that they are able to use the applicat ion. The practice pills are a commercially 
available product (ie, small white or colored candies) and will be provid ed by  AiCure.
If a subject is persistent ly noncom pliant wi th the study  drug (eg, ≥4 consecutive doses missed 
and/or <70% compliant between visit s),the medical  monitor shoul d be consul ted to discuss 
whether it may  be appropri ate to wi thdraw the subject fro m the study . All subjects shoul d be 
reinstructed about the dosing requirements during study  contacts. The authori zed study  personnel 
conducting the re -education must document the process in the subject source records. 
9.3 Schedule of Observations and Procedur es
The schedule for all study -related procedures for all evaluat ions is shown in Appendix A.
Assessments should be co mpleted at the designated visit/time po int(s).
9.4 Biological Sample Retention and Destruction
In this study, specimens for genome/gene analysis will be collected as descr ibed in Section 9.1.15 . 
The genetic material will be preserved and init ially stored at Central Laboratory  and then at 
 for up to but not lo nger than 15 years or as required by applicable law. The 
sponsor has put into place a system to protect the subjects’ personal informat ion to ensure optima l 
confident iality and defined standard processes for sample and data collect ion, storage, analysis, 
and destruction.
The sponsor and researchers working with the sponsor will have access to the samples collected 
and any  test resul ts. All  samples collected during the study  will be stored securely  with limited 
access and the sponsor will require anyo ne who works with the samples to agree to hold the 
research informat ion and any results in confidence.
The sample will be labeled with a unique sample ident ifier similar to labeling in the main study but 
using a code that is different from the code attached to the health information and other clinical test 
resul ts collected in the study . The sample and data are linked to personal health informat ion with 
code numbers. This link means that the subject may be ident ified but only indirect ly. The code 
numbers will be k ept secure by  or on behalf of the sponsor.
Subjects who consented and provided PGx blood samples for DNA and RNA analysis can 
withdraw their consent and request disposal o f a stored sample at any t ime. The sponsor should be 
notified o f any wit hdrawal o f consent. Notify sponsor of consent withdrawal.
PPD
PPD
Vortioxetine
Study No. Vortioxetine -4001 Page 51of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL10.0 PRETREATMENT EVENTS AND ADVERSE EVENTS
10.1 Definitions
10.1.1 PTEs
A PTE i s defined as any  untoward m edical  occurrence in a clinical invest igation subject who has 
signed inform ed consent to participate in a study  but pri orto administration of any study  drug; i t 
does not necessarily  have to have a causal relat ionship wit h study  parti cipat ion.
10.1.2 AEs
An AE is defined as any untoward medical occurrence in a clinical invest igation subject 
administered a drug; it does not necessar ily have to have a causal relat ionship with this treatment.
An AE can therefore be any unfavorable and unintended sign (eg, a clinically significant abnormal 
laboratory  value), symptom, or disease temporally associated with the use o f a drug whether or not
it is considered related to the drug.
10.1.3 Additional Points to Consider for PTEs and AEs
An untoward finding generally may:
Indicate a new diagnosis or unexpected worsening of a pre- exist ing condit ion. (Intermittent 
events for pre -exist ing condit ions or underlying disease should not be considered PTEs or 
AEs.)
Necessitate therapeutic intervent ion.
Requi re an invasive diagnostic procedure.
Requi re discont inuat ion or a change in dose of study  drug or a concomitant medicat ion.
Be considered unfavorable by th e invest igator for any reason.
PTEs/AEs caused by a study  procedure (eg, a bruise after blood draw) should be recorded as a 
PTE/AE.
Diagnoses vs signs and symptoms:
Each event should be recorded to represent a single  diagnosis. Acco mpanying signs (includin g 
abnorm al laboratory  values) or symptoms should NOT be recorded as addit ional AEs. If a 
diagnosis is unknown, sign(s) or symptom(s) should be recorded appropriately as a PTE(s) or 
as an AE(s).
Laboratory  values findings:
Changes in laboratory  values are o nly considered to be PTEs or AEs if they are judged to be 
clinically significant (ie, if so me act ion or intervention is required or if the invest igator judges 
the change to be beyo nd the range of normal physiologic fluctuation). A laboratory  re-test 
and/or continued mo nitoring of an abnormal value are not considered an intervent ion. In 
Vortioxetine
Study No. Vortioxetine -4001 Page 52of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALaddition, repeated or addit ional noninvasive testing for verificat ion, evaluat ion, or m onitoring 
of an abnorm ality is not considered an intervention.
If abnormal laboratory v alues are the result of pathology for which there is an overall diagnosis 
(eg, increased creatinine in renal failure), the diagnosis only should be reported appropriately 
as a PTE or as an AE.
Pre-exist ing condit ions:
Pre-exist ing condit ions (present at th e time o f signing of informed consent) are considered 
concurrent medical condit ions and should NOT be recorded as PTEs or AEs. Baseline 
evaluat ions (eg, l aboratory  tests, X -rays) should NOT be recorded as PTEs unless related to 
study  procedures. However, i f the subject experi ences a worsening or complicat ion of such a 
concurrent medical condit ion, the worsening or complicat ion should be recorded appropriately 
as a PTE (worsening or complication occurs before start of study drug) or an AE (worsening or 
complication occurs after start of study  drug). Investigators should ensure that the event term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
If a subject has a pre -exist ing episodic concurrent medical condit ion (eg, asthma, epilepsy) any
occurrence of an episode should only be captured as a PTE/AE if the condit ion beco mes more 
frequent, serious or severe in nature. Investigators should ensure that the AE term recorded 
captures the change in the condit ion from Baseline (eg “worsening of…”) .
If a subject has a degenerat ive concurrent medical condit ion (eg, cataracts, rheumatoid 
arthri tis), worsening of the condition should only  be recorded as a PTE/AE if occurring to a 
greater extent to that which would be expected. Investigators should ensu re that the AE term 
recorded captures the change in the condit ion (eg, “worsening o f…”).
Worsening of PTEs or AEs:
If the subject experiences a worsening or complication of a PTE after the start of study  drug, 
the worsening or complication should be record ed appropriately as an AE. Invest igators should 
ensure that the AE term recorded captures the change in the PTE (eg, “worsening of…”).
If the subject experiences a worsening or complication of an AE after any  change in study  
drug, the worsening or complica tion shoul d be recorded as a new AE. Invest igators should 
ensure that the AE term recorded captures the change in the condit ion (eg, “worsening of…”).
Changes in intensit y of AEs /Serious PTEs:
If the subject experiences changes in intensit y of an AE/seri ous PTE, the event should be 
captured once with the maximum intensit y recorded.
Prepl anned procedures (surgeries or intervent ions):
Prepl anned procedures (surgeries or therapies) that were scheduled prior to signing of 
inform ed consent are not considered PT Es or AEs. However, if a preplanned procedure is 
perform ed early  (eg, as an emergency) due to a worsening of the pre -exist ing condit ion, the 
Vortioxetine
Study No. Vortioxetine -4001 Page 53of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALworsening of the condit ion shoul d be recorded as a PTE or an AE. Complications result ing 
from any planned surgery  should be reported as AEs.
Elect ive surgeries or procedures:
Elect ive procedures performed where there is no change in the subject’s medical condit ion 
shoul d not be recorded as PTEs or AEs, but should be documented in the subject’s source 
docum ents. Com plications result ing from an elect ive surgery should be reported as AEs.
Insufficient clinical response (lack of efficacy):
Insufficient clinical response, efficacy, or pharmacologic act ion, should NOT be recorded as 
an AE. The invest igator must make the distinction bet ween exacerbation o f pre-exist ing illness 
and lack of therapeutic efficacy.
Overdose:
Cases of overdose with any  medicati on wi thout m anifested si de effects are NOT considered 
PTEs or AEs, but instead will be documented on an Overdose page of the eCRF. Any  
manifested side effects will be considered PTEs or AEs and will be recorded on the AE page of 
the eCRF.
Suicidali ty events:
A co mpleted suicide is always an SAE based on its fatal outcome. Addit ionally , for the 
purpose of this development pr ogram , active suicidal behaviors such as “suicidal intent ion 
with a defini te plan” and “suicide attempt” will also be collected as SAEs. Unless the event 
meets other serious criteria, suicidal thoughts or suicidal ideations that do not include a definit e 
plan or acti on will be collected as nonserious AEs in accordance wit h the standard AE 
reporting requirements (eg, if a pre -exist ing suicidal ideat ion recorded on the screening 
C-SSRS got worse during the study, it should be reported as an AE). A subject pre senting with 
self-mutilat ion or other ty pes of  self-injury  should be quest ioned by  the invest igator to clarify 
if the act ion was suicidal in intent. If the event was suicidal in intent, the invest igator should 
include suicidal behavior as part of the verba tim term on the eCRF, that is, “slit wrists/suicidal 
behavior.” Such an event will be co llected as an SAE. Acts of self -mutilat ion or self -injury 
without sui cidal  intention, for example, self -imposed cigarette burns, will be collected as 
nonseri ous AEs.
10.1.4 SAEs
An SAE is defined as any untoward medical occurrence that at any  dose:
1.Results in DEATH.
2.Is LIFE THREATENING.
The term “life threatening” refers to an event in which the subject was at risk of death at the 
time of the event; it does not refer to an even t that hypotheti cally  might have caused death 
if it were m ore severe.
Vortioxetine
Study No. Vortioxetine -4001 Page 54of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL3.Requi res inpat ient HOSPITALIZATION or prolongation of exist ing hospitalizat ion.
4. Results in persistent or significant DISABILITY/INCAPACITY.
5.Is a CONGENITAL ANOMALY/BIRTH DEFECT.
6.Is an IM PORTANT MEDICAL EVENT that satisfies any of the fo llowing:
May require intervent ion to prevent items 1 through 5 above.
May expose the subject to danger, even though the event is not immediately life 
threatening or fatal or does not result in hospitalizati on.
Includes any event or synonym described in the Takeda Medically  Significant AE List 
(Table 10.a).
Table 10.a Takeda Medically Significant AE List 
Term
Acute respiratory failure/acute respiratory distress 
syndromeHepatic necrosis
Acute liver failure
Torsade de pointes/ventricular fibrillation/ventricular 
tachycardiaAnaphy lactic shock
Acute renal failure
Malignant hypertension Pulmonary hypertension
Convulsive seizure Pulmonary fibrosis 
Agranulocytosis Confirmed or suspected endotoxin shock
Aplastic anemia Confirmed or suspected transmission of infectious agent by a 
medicinal product
TEN/SJS Neuroleptic malignant syndrome/malignant hyperthermia
Spontaneous abortion/stillbirth and fetal death
SJS= Stevens -Johnson syndrome , TEN= Toxic epidermal necrolysis .
PTEs that fulfill 1 or more of the serious criteria above are also to be consider ed SAEs and should 
be reported and fo llowed up in the same manner (see Sections 10.2.2 and 10.3) .
10.1.5 Special Interest Adverse Events
A special interest AE (serious or nonserious) is one of scientific and medical concern specific to 
the com pound or program , for which ongoing monitoring and rapid communicat ion by the 
investigator to Takeda may be appropriate. Such events may require further invest igation in order 
to characterize and understand them and would be described in protocols and instructions provided 
for invest igators as to how and when th ey shoul d be reported to Takeda.
10.1.5.1 Skin and Allergic Type Reactions
Any subject who develops rash should undergo assessment to characterize the nature and locat ion 
of the rash. Subjects should be adequately  examined for any  clinical features that might sugge st a 
developing drug reaction with eosinophilia and systemic symptoms (DRESS), a developing TEN, 
Vortioxetine
Study No. Vortioxetine -4001 Page 55of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALor SJS. For example, all subjects who develop rash should undergo a physical examinat ion and be 
monitored for the appearance of any  of the f ollowing features ( and findings should be recorded):
a)Involvement of mucous membranes or conjunctiva.
b)The development of skin pain.
c)Urticaria, blistering, other skin lesio ns.
d)Any evidence of angioedema.
If there are subjects with symptoms of systemic reaction (eg, generalized rash), or signs of a severe 
rash (such as those outlined above), or if clinically appropriate, then the fo llowing laboratory  tests 
shoul d also be perform ed and the results monitored accordingly: co mplete blood count with 
different ials, liver and renal fun ctions tests, and urinalysis.
Any subjects showing symptoms or signs outlined above, or if clinically indicated, should also be 
assessed by a dermatologist and undergo an adequate diagnostic work -up (to assess for developing 
DRESS, TEN, or SJS).
Finally , consider taking photographs of rashes and, when appropriate, obtain skin biopsies.
For all cases of rash where an alternative causalit y is not known, the Skin -or Allergy -Type 
React ion page of the eCRF should be co mpleted wit hin 1 business day o f the invest igator’s 
awareness o f the event. If the alternat ive causalit y has been ident ified, then the Skin -or 
Allergy -Type React ion page of the eCRF should not be completed.
10.1.5.2 Liver Injury
Management of liver toxicit y AE s is described in Section 7.4. If ALT or AST >3×ULN, laboratory 
tests shoul d be repeated wi thin a maximum of 7 days, and preferably  within 48 to 72 hours. If the 
ALT or AST remains elevated >3×UL N on these 2 consecutive occasio ns, and this observat ion 
cannot be explained by conco mitant disease or another alternat ive causalit y, the abnorm ality 
shoul d be recorded on an AE page of the eCRF. The invest igator must contact the medical mo nitor 
for consi deration of  immediate discont inuat ion of study drug and discussio n of relevant subject 
details and possible alternat ive causalit ies.
For events that meet the criteria described in Sect ion
 7.4,the Liver Injury page of the eCRF should 
be co mpleted within 1 business day  of the invest igator’s awareness of the event.
10.1.5.3 Overdose
Management of an overdose is described in Section 8.1.4 . All cases of overdose (with or without 
associ ated AEs) will be documented as AEs. For events that meet the criteria of an overdose, the 
Overdose page of the eCRF should be completed within 1 business day  of the investi gator’s 
awareness o f the event.
Vortioxetine
Study No. Vortioxetine -4001 Page 56of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL10.1.6 Intensity of PTEs and AEs
The different categories o f intensit y (severit y) are characteri zed as follows:
Mild: The event is transient and easily tolerated by the subject.
Moderate: The event causes the subject discomfort and interrupts the subject’s usual activities.
Severe: The event causes considerable interference with the subject’s usual activities.
10.1.7 Causality of AEs
The rel ationship of each AE to study  drug will be assessed using the fo llowing categori es:
Related: An AE that follows a reasonable temporal sequence from administration of a drug (including the 
course after withdrawal of the drug), or for which possible involvement of the drug cannot be 
ruled out , although factors other than the drug, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments, may also be responsible.
Not Related: An AE that does not follow a reasonable temporal sequence from administration of a drug and/o r 
that can reasonably  be explained by other factors, such as underlying diseases, complications, 
concomitant medications, and concurrent treatments.
10.1.8 Relationship to Study Procedures
Relationship (causalit y) to study  procedures should be determined for all PTEs and AEs.
The relationship should be assessed as Related if the investigator considers that there is reasonable 
possibilit y that an event is due to a study procedure. Otherwise, the relationship should be assessed 
as Not Related. 
10.1.9 Start Date
The start date of t he AE/PTE is the date that the first signs/symptoms were noted by the subject 
and/or invest igator.
10.1.10 Stop Date 
The stop date of the AE/PTE is the date at which the subject recovered, the event resolved but with 
sequelae, or the subject died.
10.1.11 Frequency 
Episodic AEs/PTEs (eg, vomit ing) or those which occur repeatedly  over a peri od of  consecutive 
days are intermittent. All other events are continuous.
10.1.12 Action Concerning Study Drug
Drug withdrawn –a study  drug i s stopped due to the particular AE.
Dose not chang ed –the particular AE did not require stopping a study  drug.
Unknown –only to be used if it has not been possible to determine what action has been taken.
Vortioxetine
Study No. Vortioxetine -4001 Page 57of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALNot Applicable –a study  drug was stopped for a reason other than the particular AE, eg, the 
study  has been terminated, the subject died, or dosing with study  drug was al ready stopped 
before the onset of the AE.
10.1.13 Outcome
Recovered/Resolved –the subject returned to first assessment status with respect to the 
AE/PTE.
Recovering/Reso lving –the intensit y is lowered by  1 or m ore stages: the diagnosis or 
signs/symptom s has almost di sappeared; the abnormal laboratory  value improved, but has not 
returned to the normal range or to baseline; or the subject died fro m a cause other than the 
particular AE/PTE with t he condit ion rem aining “recovering/reso lving.”
Not recovered/not resolved –there is no change in the diagnosis, signs or symptoms; the 
intensity of the di agnosis, si gns/symptoms, or laboratory  value on the last day  of the observed 
study  period has got wor se than when it started; the event is an irreversible congenital 
anomaly; the subject died from another cause with the particular AE/PTE state remaining “not 
recovered/not resolved.”
Reso lved with sequelae –the subject recovered from an acute AE/PTE but w as left with 
perm anent/si gnificant impairment (eg, recovered from a cardiovascular accident but with 
some persisting paresis.
Fatal  –the AEs/PTEs are considered as the cause of death. 
Unknown –the course of the AE/PTE cannot be followed up due to hospit al change or 
residence change at the end of the subject’s participation in the study .
10.2 Procedures
10.2.1 Collection and Reporting of AEs
Collect ion of PTEs will co mmence from the time the subject signs the informed consent to 
participate in the study and cont inue until the subject is first administered study drug (on Day 1) or 
until screen failure. For subjects who discont inue prior to study drug administration, PTEs are 
collected unt il the subject discont inues study  parti cipat ion.
Collect ion of AEs will co mmence f rom the time that the subject is first administered study  drug 
(on Day  1). Routine collection of AEs will cont inue until the Fo llow-up Contact (Week 7) .
10.2.1.1 PTE and AE Reporting
At each study  visit, the investi gator will assess whether any  subjective AEs have occurred. A 
neutral  quest ion, such as “How have you been feeling since your last visit ?” may be asked. 
Subjects m ay report AEs occurri ng at any  other time during the study . Subjects experi encing a 
serious PTE m ust be monitored until the symptoms subside and any clinically relevant changes in 
laboratory  values have returned to baseline or there is a sat isfactory  explanati on for the change. 
Vortioxetine
Study No. Vortioxetine -4001 Page 58of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALNonserious PTEs, related or unrelated to the study  procedure, need not to be fo llowed-up for the 
purposes of the protoc ol.
All subjects experiencing AEs, whether considered associated with the use of the study  drug or 
not, m ust be m onitored until  the symptoms subside and any clinically  relevant changes in 
laboratory  values have returned to baseline or until there is a sati sfactory  explanat ion for the 
changes observed. All PTEs and AEs will be documented in the PTE/AE page of the eCRF, 
whether or not the invest igator concludes that the event is related to the drug treatment. The 
following informat ion will be documented for e ach event:
1.Event term .
2.Start and stop date and time .
3.Frequency.
4.Intensit y.
5.Invest igator’s opinio n of the causal relat ionship between the event and administration of study 
drug (rel ated or not rel ated) (not completed for PTEs).
6.Invest igator’s opinio n of the causal relat ionship to study  procedure(s), including the details of 
the suspected procedure.
7.Action concerning study  drug (not applicable for PTEs) .
8.Outcom e of event .
9.Seriousness .
The CSFQ -14, PGI -I scale, and C -SSRS will not be used as a primary  means to collect AEs. 
However, should the invest igator become aware of a potential AE through the information 
collected with these instruments, proper follow -up wi th the subject for m edical evaluat ion shoul d 
be undertaken. Through this fo llow-up, if it is determin ed that an AE not previously  reported has 
been ident ified, normal reporting requirements should be applied.
10.2.1.2 Special Interest Adverse Event Reporting
If the subject experiences a skin rash or allergic -type event as described above, liver injury , or 
overdose during the Treatment Period or the safet y Follow-up Period based on the criteria outlined 
in Section 10.1.5 ,the event should be reported on a specific page of the eCRF wi thin 1 business 
day of the invest igator’s awareness. Any relevant supporting documentation (ie, photographs, 
additional diagnosti c testing, consultation reports) must be submitted to the sponsor. The special 
interest AEs have to be recorded as AEs in the eCRF.
Vortioxetine
Study No. Vortioxetine -4001 Page 59of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL10.2.2 Collection and Reporting of SAEs
When an SAE occurs through the AE collection period it should be reported according to the 
following procedure:
A Takeda SAE form must be co mpleted, in English, and signed by the investigator immediately or 
within 24 hours of first onset or notificat ion of the event. The informat ion should be completed as 
fully as possible but contain, at a minimum:
A short descript ion of the event and the reason why  the event i s categori zed as serious.
Subject ID number.
Invest igator’s name.
Nam e of the study  drug(s).
Causalit y assessment.
The SAE form should be transmitted within 24 hours to the attention of the contact listed in 
Secti on 1.1.
Any SAE spontaneously reported to the invest igator fo llowing the AE collect ion period should be 
reported to the sponsor if considered related to study  parti cipat ion.
Reporting of serious PTE s will fo llow the procedure described for SAEs.
10.2.3 Reporting of Abnormal LFTs
If a subject is noted to have ALT or AST elevated >3×ULN on 2 consecutive occasions, the 
abnorm ality should be recorded as an AE. In addit ion, the LFT Increases page of the eCRF mus t be 
completed provi ding addi tional information on relevant recent history , risk factors, clinical signs 
and symptoms, and results o f any addit ional diagnostic tests performed.
If a subject is noted to have ALT or AST >3 ×ULN and total bilirubin >2 ×ULN for which an 
alternat ive etio logy has not been i dentified, the event should be recorded as an SAE and reported 
as per Secti on 10.2.2 . The investigator m ust con tact the m edical m onitor for discussi on of the 
relevant subject details and possible alternative etiologies, such as acute viral hepat itis A or B, 
other acute liver disease, ormedical history /concurrent m edical  condi tions. Foll ow-up laboratory  
tests as described in Section
 9.1.12 must also be performed. In addition, the LFT Increases page of 
the eCRF must be completed and transmitted with the Takeda SAE form (as per Section 10.2.2 ).
10.3 Follow -up of SAEs
If informat ion not available at the time of the first report becomes available at a later date, the 
investigator should complete a fo llow-up SAE form  or provi de other wri tten docum entati on and 
fax it immediately wit hin 24 hours of receipt . Copies of any relevant data from hospital notes 
(eg,ECGs, laboratory  test resul ts, di scharge summary , postmortem resul ts) shoul d be sent to the 
addressee, if requested.
Vortioxetine
Study No. Vortioxetine -4001 Page 60of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAll SAEs should be fo llowed up unt il reso lution or perm anent outcome of the event. The timelines 
and procedure for follow -up reports are the same as those for the init ial report.
10.3.1 Safety Repor ting to Investigators, IRBs, and Regulatory Authorities
The sponsor will be responsible for reporting all suspected unexpected serious adverse react ions 
(SUSARs) and any other applicable SAEs to regulatory  authori ties, invest igators, and IRBs, as 
applicabl e. Relat ive to the first awareness of the event by/or further provisio n to the sponsor or 
sponsor’s designee, SUSARs will be submitted to the regulatory authorit ies as an expedited report
within 7 days for fatal and life -threatening events and 15 days for other serious events, unless 
otherwi se requi red by  national regulat ions. The sponsor will also prepare an expedited report for 
other safet y issues where these might materially alt er the current benefit -risk assessment of a study 
drug/sponsor -supplied drug or that would be sufficient to consider changes in the study 
drug/sponsor -supplied drug administration or in the overall conduct of the trial. The study site also  
will forward a copy  of all expedited reports to their IRB.
Vortioxetine
Study No. Vortioxetine -4001 Page 61of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL11.0 STUDY- SPECIFIC COMMITTEES
No stee ring committee, data safety mo nitoring committee, or clinical endpoint committee will be 
used in this study .
Vortioxetine
Study No. Vortioxetine -4001 Page 62of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL12.0 DATA HANDLING AND RE CORDKEEPING
The full details of procedures for data handling will be documented in the Data Management Plan. 
AEs, PTEs, medical history , and concurrent m edical  condi tions will be coded using the Medical 
Dictionary for Regulatory  Activities (MedDRA). Drugs will be coded using the WHO Drug 
Dictionary.
12.1 Case Report Forms (Electronic)
Com pleted eCRFs are required for each subject who s igns an informed consent.
The sponsor or its designee will supply study  sites wi th access to eCRFs. The sponsor will make 
arrangements to train appropriate site staff in the use of the eCRF. These forms are used to transmit  
the informat ion collected in the performance of this study to the sponsor and regulatory authorities. 
The eCRFs must be completed in English.
After complet ion of the entry process, computer logic checks will be run to identify items, such as 
inconsistent dates, missing data, and question able values. Queries may  be issued by Takeda 
personnel (or designees) and will be answered by the site. 
Correcti ons to eCRFs are recorded in an audit trail that captures the old information, the new 
inform ation, identificat ion of the person making the cor rection, the date the correction was made, 
and the reason for change. Reasons for significant corrections should addit ionally be included. 
The principal invest igator must review the eCRFs for completeness and accuracy and must sign 
and date the appropriat e eCRFs as indicated. Furthermore, the investigator must retain full 
responsibilit y for the accuracy  and authent icity of all data entered on the eCRFs .
After lock of the study  database, any change o f, modificat ion of, or addit ion to the data on the 
eCRFs s hould be m ade by  the invest igator with use of change and modificat ion records of the 
eCRF sprovi ded by  the sponsor . The principal investigator must review the data change for 
completeness and accuracy, and must sign and date.
eCRFs will be reviewed for com pleteness and acceptabilit y at the study  site during peri odic visi ts 
by the sponsor or its designee. The sponsor or its designee will be permitted to review the subject’s 
medical and hospital records pertinent to the study  to ensure accuracy  of the eCRFs. The 
completed eCRFs are the sole property  of the sponsor and should not be made available in any 
form to thi rd parti es, except for authorized representatives o f appropri ate governmental healt h or 
regul atory  authori ties, wi thout wri tten permission of the sp onsor.
12.2 Record Retention
The invest igator agrees to keep the records stipulated in Section 12.1 and those documents that 
include (but are not limited to) the study -specific documents, the ident ificat ion log of all 
participat ing subjects, medical records, temporary media such as thermal sensit ive paper, source 
worksheets, all original signed and dated informed consent forms, subject authorizat ion forms 
regarding the use of personal healt h information (if separate from the informed consent forms), 
electroni c copi es of eCRFs, including the audit trail, and detailed records of drug disposit ion to 
Vortioxetine
Study No. Vortioxetine -4001 Page 63of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALenable evaluat ions or audits from regulatory  authori ties, the sponsor, or its designees. Any source 
docum entati on printed on degradable thermal sensitive paper should be photocopied by the site 
and filed wit h the original in the subject’s chart to ensure long -term legibilit y. Furthermore, 
International Conference on Harm onisati on (ICH) E6 Secti on 4.9.5 requi res the investigator to 
retain essential documents specified in ICH E6 (Section 8) until at least 2 y ears after the last 
approval  of a market ing applicat ion for a specified drug indicat ion being invest igated or, if an 
applicat ion is not approved, until at least 2 years after the invest igation is discont inued and 
regul atory  authori ties are notified. In addit ion, ICH E6 Secti on4.9.5 states that the study  records 
shoul d be retained unt il an amount of time specified by applicable regulatory  requirements or for a 
time specified in the study  site agreem ent between the invest igator and sponsor.
Refer to the study  site agreement for the sponsor’s requirements on record retention. The 
investigator should contact and receive written approval  from the sponsor before disposing of any 
such documents.
Vortioxetine
Study No. Vortioxetine -4001 Page 64of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL13.0 STATISTICAL METHODS
13.1 Statistical and Analytical Plans
A stati stical analysis plan will be prepared and finalized prior to unblinding of subject treatment 
assignments. This document will provide further details regarding the definit ion of analysis 
variables and analysis methodology  to address all study  objectives.
A blinded data review will be conducted prior to unblinding of subject treatment assignments. This 
review will assess the accuracy  and com pleteness of the study  database, subject evaluabilit y, and 
appropriateness of the planned statist ical methods.
13.1.1 Analysis Sets
The full analysis set (FAS) will include all subjects who were randomized, received at least 1 dose 
of doubl e-blind study  drug, and have at l east 1 valid postbaseline value for assessment of the 
primary  efficacy  endpoint. In FAS efficacy  summari es, subjects will be analyzed by the treatment  
to which they  were randomized.
To adj ust for treatm ent noncom pliance, one or mo re modified FAS populat ions will be defined. 
The per -protocol  analysis set (PPS) will include all subjects in the FAS who had no major protocol 
violations. Subjects to be excluded from the PPS, whether due to protocol vio lations or 
nonco mpliance to the do sing schedule, will be identified in the minutes of the subject evaluabilit y 
assessment performed prior to unblinding.
The safet y analysis set will include all subjects who were randomized and received at least 1 dose 
of doubl e-blind study  drug. In safet y summaries, subjects will be analyzed according to the 
treatm ent they  received. In the event that a subject receives more than 1 treatment, the actual 
treatm ent will be defined as the one that is used most frequently. If the 2 most commo n treatments 
are use d with equal frequency, then the rando mized treatment will be used as the actual treatment.
13.1.2 Analysis of Demographics and Other Baseline Characteristics
Baseline characterist ics will be listed and summarized for demographics (sex, age, Hispanic 
ethnicit y, race, and BMI), physical examinat ions (including assessment of menopausal status), and 
medical history  (including psychiatric history ).
Baseline values for efficacy  and safet y variables will be presented in the tables that summarize 
data per study  visit; however, baseline efficacy  data will also be presented separately for all 
subjects randomized.
For continuous variables, treatment groups will be compared using an analysis of variance with 
treatm ent and center as factors. For categorical variables, treatmen t groups will be co mpared using 
the Cochran -Mantel -Haenszel general associat ion test, stratified by  center. P -values will be 
displayed as descriptive statist ics of co mparabilit y.
Vortioxetine
Study No. Vortioxetine -4001 Page 65of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL13.1.3 Efficacy Analysis
13.1.3.1 Primary Analysis
Mean change fro m Baseline in the CSFQ -14 total score difference for vortioxet ine vs paroxet ine 
after 5 weeks of treatment will be the primary endpoint. The primary  analysis will be based on 
analysis of covariance (ANCOVA) using the last observat ion carri ed forward (LOCF) technique, 
with treatment, center, and sex as fixed factors, and baseline CSFQ -14 total score as covariate. The 
comparisons will be between each vortioxet ine dose (10 or 20 mg) and paroxetine, and both 
statist ical t ests will be 2 -sided. The Holm -Bonferroni method will be used to ad just for mult iplicity 
and control the familywise t ype I error rate at a significance level o f 0.05. If the sm aller of the 
2 p-values is <0.025, significance is obtained for the associated vortioxet ine dose and the other 
dose will then be evaluated at a 0.0 5 significance level. Alt hough vortioxet ine will be co mpared 
with paroxetine in the primary analysis, paroxetine will also be co mpared wit h placebo to validate 
the study .
13.1.3.2 Secondary Analyses
Change from Baseline in CSFQ -14 total  score for vorti oxetine vs pa roxetine, paroxetine vs 
placebo, and vorti oxetine vs pl acebo at each visit will also be analyzed using ANCOVA and 
LOCF, wi th treatm ent, center, and sex as fixed factors, and baseline CSFQ -14 total  score as 
covari ate. Similar analyses will also be performed for the m ale and female subgroups. 
Com parisons to pl acebo will be made at the significance level o f 0.05 outside o f multiplicit y 
control .
The percentage of subjects meeting criteria for sexual dysfunct ion (ie, CSFQ -14 total score ≤47 for 
men and ≤41 for w omen) at any visit (using LOCF) during the double -blind Treatment Period will 
be analyzed by logist ic regressio n, adjust ing for baseline CSFQ -14 total  score, sex, and treatment.
Change from Baseline in CSFQ -14 subscales 5 dimensions and 3 phases of the sex ual response 
cycle will  be analyzed at all visit s using ANCOVA and LOCF similar to the primary analysis.
13.1.3.3 Additional Analyses
The percentage of subjects meeting criteria for sexual dysfunct ion (ie, CSFQ -14 total score ≤47 for 
men and ≤41 for wom en) at any  2consecut ive visits (using LOCF) during the double -blind 
Treatment Period will be analyzed by logist ic regressio n, adj usting for baseline CSFQ -14 total  
score, sex, and treatment.
Time to sexual dysfunct ion as assessed by the CSFQ -14 will be analyzed using a Cox model wit h 
an exact m ethod to handle ties, with treatment and sex as factors.
CSFQ -14 shift fro m no rmal (ie, CSFQ -14 total score >47 for men and >41 for women) at Baseline 
to abnormal (ie, CSFQ -14 total  score ≤47 for men and ≤41 for women), and CSFQ -14 negat ive 
responders (decrease from Baseline in CSFQ -14 total  score ≥3) will be analyzed at all visit s by 
logistic regressio n, adj usting for baseline CSFQ -14 total  score, sex, and treatment.
Vortioxetine
Study No. Vortioxetine -4001 Page 66of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALPGI-I will be analyzed by study visit using ANCOVA and LOCF, wi th treatm ent, center, and sex 
as fixed factors.
C-SSRS will be summarized by study  visit for each treatment group using descript ive statist ics.
13.1.4 PK Analysis
Plasma concentrations o f vorti oxetine and paroxet ine will be presented in the data list ings.
A popul ation PK analysis will only be conducted for vortioxet ine and/or paroxetine if deemed 
necessary . 
13.1.5 PGx Analysis
DNA samples may be used to analyze the mode of action of vortioxet ine, and RNA samples may 
be used for subsequent pathway analysis. Also, since P Gx is an evo lving science, many genes and 
their functions are not yet fully understood. Future data may suggest a role of some of these genes 
in drug response, which may lead to addit ional hypothesis -generat ing exploratory research and 
diagnosti c devel opme nt using stored samples.
13.1.6 Safety Analysis
AEs
AEs will be reported throughout the study . AEs will  be summarized using the safet y analysis set.
The definit ion of treatment -emergent AEs will be provided in the statist ical analysis plan. AEs will 
be coded using MedDRA and will be summarized by system organ class and preferred term for the 
doubl e-blind Treatment Period and the ent ire study.
AEs that were reported more than once by a subject during the double -blind Treatment Period will 
be counted only once f or that subj ect at the m aximum  severi ty.
Clinical Evaluations
Absolute values and changes from Screening/Baseline for clinical laboratory tests, vital signs, and 
weight will be summarized for each treatment group using descriptive statist ics. Clinical 
laboratory  test and vi tal sign resul ts that are outsi de the norm al ranges and potenti ally clinically 
significant will be flagged and tabulated. Phy sical examinat ion findings will also be summarized 
for each treatm ent group.
13.2 Interim Analysis and Criteria for Ea rly Termination
No interim analysis is planned.
13.3 Determination of Sample Size
Approximately  352 male and female subjects will be randomized to 4 treatment arms.
Vortioxetine
Study No. Vortioxetine -4001 Page 67of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAssuming an SD of 8.5 for the change fro m Baseline in CSFQ- 14 total  score, a total  of 352 m ale 
and female subjects (88 subjects per arm) is sufficient to achieve ≥80% power to detect a 
difference of 4.0 for vortioxetine 20 mg vs paroxetine 20 mg or for vortioxet ine 10 mg vs 
paroxetine 20 mg by a 2- sample t-test wi th a 0.025 2- sided significance leve l.Given the proposed 
Holm- Bonferroni  method for m ultiplicity control , the power to achieve the significance for each 
vorti oxetine dose is approximately  85%.
Vortioxetine
Study No. Vortioxetine -4001 Page 68of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL14.0 QUALITY CONTROL AND QUALITY ASSURANCE
14.1 Study -Site Monitoring Visits
Moni toring visit s to the study  site will  be made peri odically  during the study  to ensure that all 
aspects of the protocol are fo llowed. Source documents will be reviewed for verificat ion of data 
recorded on the eCRFs. Source documents are defined as original documents, data, and records . 
The invest igator and study site guarantee access to source documents by the sponsor or its 
designee (contract research organization) and by the IRB.
All aspects of the study  and i ts docum entati on will be subject to review by the sponsor or its 
designee ( as long as blinding is not jeopardized), including but not limited to the Investigator’s 
Binder, study  drug, subject m edical records, informed consent documentation, documentation of 
subject authorizat ion to use personal healt h information (if separate fro m the inform ed consent 
forms), and review o f eCRFs and associated source documents. It is important that the invest igator 
and other study  personnel are available during the mo nitoring visits and that sufficient time is 
devoted to the process.
14.2 Protocol Devi ations
The invest igator should not deviate fro m the protocol , except where necessary  to eliminate an 
immediate hazard to study subjects. Should other unexpected circumstances arise that will require 
deviat ion from protocol -specified procedures, the investi gator shoul d consul t with the sponsor or 
designee (and IRB, as required) to determine the appropriate course of action. There will be no 
exempt ions (a prospectively  approved deviat ion) from the inclusio n or excl usion cri teria.
The site should document all protocol  deviat ions in the subject’s source documents. In the event of 
a significant devi ation, the si te shoul d notify  the sponsor or i ts desi gnee (and IRB, as required). 
Significant deviat ions include, but are not limited to, those that invo lve fraud or m isconduct, 
increase the healt h risk to the subject, or confound interpretation of primary study  assessment. A 
Protocol  Deviat ion Form should be completed by the site and signed by the sponsor or its designee 
for any  significant devi ation from the protocol.
14.3 Quality Assurance Audits and Regulatory Agency Inspections
The study  site also m ay be subject to qualit y assurance audi ts by  the sponsor or i ts desi gnees. In 
this circumstance, the sponsor -designated audi tor will  contact the si te in advance to arrange an 
auditing visit. The auditor may ask to visit the facilit ies where laboratory  samples are collected or 
where the study  drug is stored and prepared, and any  other facili ty used during the study . In 
addition, there i s the possibilit y that thi s study  may be in spected by  the US regul atory  agency, the 
FDA. If the study  site is contacted for an inspect ion by the FDA, the sponsor should be notified 
immediately . The invest igator and study site guarantee access for qualit y assurance auditors to all 
study  docum ents as described in Section 14.1.
Vortioxetine
Study No. Vortioxetine -4001 Page 69of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL15.0 ETHICAL ASPECTS OF T HE STUDY
This study  will be conducted wi th the highest respect for the individual participants (ie, subjects) 
according to the protocol, the ethical principles that have their origin in the Declaration o f 
Helsinki, and the ICH Harmonised Tripart ite Guideline for GCP. Each investigator will conduct 
the study  according to applicable local or regional regul atory  requi rements and align his or her 
conduct in accordance with the “Responsibilit ies of the Invest igator” that are listed in Appendix B. 
The princi ples of Helsinki are addressed through the protocol and through appendices containing 
requi rements for informed consent and invest igator responsibilit
ies.
15.1 Institutional Review Board Approval
IRBs m ust be consti tuted according to the applicable state and fe deral requi rements of each 
participat ing region. The sponsor or its designee will require documentation noting all names and 
titles of members who make up the respective IRB. If any member of the IRB has direct 
participat ion in this study , written notifica tion regarding his or her abst inence fro m voting must 
also be obtained. Those Americas sites unwilling to provide names and t itles of all members due to 
privacy  and conflict of interest concerns should instead provide a Federal Wide Assurance 
Number or com parable number assigned by  the Departm ent of Healt h and Human Services.
The sponsor or its designee will supply relevant documents for submissio n to the respective IRB 
for the protocol’s review and approval. This protocol, the Invest igator’s Brochure, a co py of the 
inform ed consent form, and, if applicable, subject recruit ment materials and/or advertisements and 
other documents required by all applicable laws and regulat ions, must be submitted to a central or 
local IRB for approval. The IRB’s written approv al of the protocol  and subject informed consent 
must be obtained and submitted to the sponsor or its designee before commencement of the study  
(ie,before shipment of the sponsor -supplied drug or study -specific screening activit y). The IRB 
approval  must refer to the study by exact protocol title, number, and versio n date; ident ify versio ns 
of other documents (eg, informed consent form) reviewed; and state the approval date. The 
sponsor will notify  the si te once the sponsor has confirmed the adequacy of site regulatory  
docum entati on and, when applicable, the sponsor has received permissio n from competent 
authori ty to begin the study . Unt il the site receives notification, no protocol activit ies, including 
screening may occur.
Study  sites m ust adhere to all req uirements st ipulated by their respect ive IRB. This may include 
notification to the IRB regarding protocol amendments, updates to the informed consent form, 
recrui tment m aterials intended for viewing by  subjects, l ocal safet y reporti ng requirements, 
reports and updates regarding the ongoing review of the study  at intervals specified by  the 
respective IRB, and submissio n of the investigator’s final status report to IRB. All IRB approvals 
and relevant documentation for these items must be provided to the spons or or i ts desi gnee.
Subject incentives should not exert undue influence for participat ion. Payments to subjects must 
be approved by the IRB and sponsor.
Vortioxetine
Study No. Vortioxetine -4001 Page 70of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL15.2 Subject Information, Informed Consent, and Subject Authorization
Written consent documents will embody  the elements of informed consent as described in the 
Declaration of Helsinki and the ICH Guidelines for GCP and will be in accordance with all 
applicable laws and regulations. The informed consent form, subject authorizat ion form (if 
applicable), and subje ct inform ation sheet (if applicable) describe the planned and permitted uses, 
transfers, and disclo sures of the subject’s personal and personal healt h informat ion for purposes of 
conducting the study. The informed consent form and the subject informat ion sheet (if applicable) 
further explain the nature of the study, its object ives, and potential risks and benefit s, as well as the 
date informed consent is given. The informed consent form will detail the requirements of the 
participant and the fact that he or she is free to withdraw at any  time wi thout giving a reason and 
without prej udice to hi s or her further m edical care.
The invest igator is responsible for the preparation, content, and IRB approval o f the inform ed 
consent form and if applicable, the subjec t authorization form. The informed consent form, subject  
authori zation form (if applicable), and subject info rmation sheet (if applicable) must be approved 
by both the IRB and the sponsor prior to use.
The informed consent form, subject authorizat ion form  (if applicable), and subject informat ion 
sheet (if applicable) must be written in a language fully co mprehensible to the prospective subject. 
It is the responsibilit y of the invest igator to explain the detailed elements of the informed consent 
form, subject authorizat ion form (if applicable), and subject informat ion sheet (if applicable) to the 
subject. Information should be given in both oral and written form whenever possible and in the 
manner deemed appropriate by  the IRB.
The subject must be given ample opportuni ty to: (1) inquire about details of the study  and 
(2)decide whether or not to participate in the study. If the subject determines he or she will 
participate in the study , then the informed consent form and subject authorizat ion form (if 
applicable) m ust be si gned and dated by  the subject at the time of consent and prior to the subject 
entering into the study . The subject shoul d be instructed to sign using their legal names, not 
nicknames, using blue or black ballpo int ink. The investigator must a lso sign and date the informed 
consent form and subject authorization (if applicable) at the time of consent and prior to subject 
entering into the study; however, the sponsor may  allow a designee of the invest igator to sign to 
the extent permitted by  appl icable law.
Once signed, the original informed consent form, subject authorization form (if applicable), and 
subject informat ion sheet (if applicable) will be stored in the invest igator’s site file. The 
investigator must document the date the subject signs the informed consent in the subject’s 
medical record. Copies of the signed informed consent form, the signed subject authorization for m 
(if applicable), and subject informat ion sheet (if applicable) shall be given to the subject.
All revised informed cons ent forms m ust be reviewed and signed by relevant subjects in the same 
manner as the original informed consent. The date the revised consent was obtained should be 
recorded in the subject’s medical record, and the subject should receive a copy  of the revis ed 
inform ed consent form .
Vortioxetine
Study No. Vortioxetine -4001 Page 71of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALSubjects who consented and provided PGx samples for DNA and RNA analysis can wit hdraw 
their consent and request disposal o f a stored sample at any  time pri or to analysis. Notify  sponsor 
of consent wi thdrawal.
15.3 Subject Confidentiali ty
The sponsor and designees affirm and upho ld the principle of the subject’s right to protection 
against invasio n of privacy. Throughout this study , a subject’s source data will only be linked to 
the sponsor’s clinical study  database or documentation via a subject ID number. As permitted by  
all applicable laws and regulations, limited subject attributes, such as sex, age, or date of birth, and 
subject init ials may be used to verify the subject and accuracy  of the subject’s unique ID number.
To com ply with ICH Guidelines for GCP and to verify co mpliance with this protocol, the sponsor 
requi res the invest igator to permit the monitor or the sponsor’s designee, representatives fro m any 
regul atory  authori ty (eg, FDA, Medi cines and Heal thcare products Regul atory  Agency, 
Pharmaceut icals and Medical Devices Agency), the sponsor’s designated auditors, and the 
appropriate IRBs to review the subject’s original medical records (source data or documents), 
including, but not limited to, laboratory  test resul t reports, ECG reports, admissio n and di scharge 
summaries for hospital admissions occurring during a subject’s study  parti cipat ion, and autopsy  
reports. Access to a subject’s original medical records requires the specific authorization o f the 
subject as part of the info rmed consent process (see Section 15.2).
Copi es of  any subject source documents that are provided to the sponsor must have certain 
personally ident ifiable informat ion rem oved (ie, subject name, address, and other ident ifier fields 
not collected on the subject’s eCRF).
15.4 Publication, Disclosure, and Clinical Trial Registration Policy
15.4.1 Publication and Disclosure
The investigator is obliged to provide the sp onsor with complete test results and all data derived by 
the invest igator from the study . During and after the study , only  the sponsor m ay make study  
inform ation available to other study  invest igators or to regulatory  agencies, except as required by  
law or regulation. Except as otherwise allo wable in the study site agreement, any public disclosure 
(including publicly accessible websites) related to the protocol or study  resul ts, other than study  
recrui tment m aterials and/or advertisements, is the sole respo nsibilit y of the sponsor.
The sponsor may publish any data and informat ion fro m the study (including data and informatio n 
generated by  the invest igator) without the consent of the invest igator. Manuscript authorship for 
any peer -reviewed publicat ion will a ppropri ately reflect contribut ions to the production and 
review of the document. All publicat ions and presentations must be prepared in accordance with 
this sect ion and the study site agreement. In the event of any discrepancy between the protocol and 
the study  site agreement, the study  site agreement will  prevail.
Vortioxetine
Study No. Vortioxetine -4001 Page 72of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL15.4.2 Clinical Trial Registration
In order to ensure that informat ion on clinical trials reaches the public in a timely manner and to 
comply with applicable laws, regulat ions, and guidance, Takeda will , at a minimum , register all  
intervent ional clinical tri als it sponsors anywhere in the worl d on ClinicalTrials.gov and/or other 
publicly  accessible websites before start of study , as defined in Takeda Policy/Standard . Takeda 
contact informat ion, along wit h invest igator’s cit y, state (for Americas investigators), country, and 
recrui ting status will be registered and available for public viewing. 
For some registries, Takeda will assist callers in lo cating study  sites cl osest to thei r homes by 
provi ding the invest igator name, address, and phone number to the callers request ing trial 
inform ation. Once subjects receive invest igator contact informat ion, they  may call  the si te 
requesting enrollment into the trial. The invest igative sites are encouraged to handle the trial 
inquiries according to their established subject screening process. If the caller asks addit ional 
questions bey ond the topic of trial enro llment, they should be referred to the sponsor.
Any invest igator who objects to the sponsor providing this informat ion to callers must provide the 
sponsor with a written notice request ing that their informat ion not be listed on the registry  site. 
15.4.3 Clinical Trial Results Disclosure
Takeda will post the results of clinical trial son ClinicalTrials.gov and/or othe r publicly accessible 
websites, as required by Takeda Policy/Standard, applicable laws and/or regulat ions.
15.5 Insurance and Compensation for Injury
Each subject in the study  must be insured in accordance with the regulations applicable to the site 
where the s ubject is parti cipat ing. If a local underwriter is required, then the sponsor or sponsor’s 
designee will obtain clinical study  insurance against the risk o f injury to study  subjects. Refer to 
the study site agreement regarding the sponsor’s policy on subje ct compensat ion and treatment for 
injury . If the invest igator has questions regarding this policy, he or she should contact the sponsor 
or sponsor’s designee.
Vortioxetine
Study No. Vortioxetine -4001 Page 73of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL16.0 REFERENCES
1.Kessler RC, Birnbaum HG, Shahly  V, Brom et E, Hwang I, McLaughlin KA, et al . Age 
differences in the prevalence and co -morbidity of DSM -IV m ajor depressive episodes: results 
from the WHO Worl d Mental Heal th Survey  Initiative. Depress Anxiet y 2010;27(4):351 -64.
2.World Health Organizat ion. Mental Health Act ion Plan 2013 -2020. Published 2013. Accessed 
08 October 2014. Available at: 
http://apps.who.int/iris/bitstream/10665/89966/1/9789241506021_eng.pdf?ua=1.
3.Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a crit ical review. J Clin 
Psychopharm acol 1999;19(1):67 -85.
4.Montejo AL, Llorca G, Izquierdo JA, Rico -Villademoros F. Incidence of sexual dysfunction 
associ ated wi th antidepressant agents: a prospective mult icenter study  of 1022 outpati ents. 
Spanish Working Group for the Study  of Psychotropi c-Related Sexual Dysfunct ion. J Clin 
Psychiatry  2001;62 Suppl 3:10 -21.
5.Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden -Watson C, et al. 
Prevalence of sexual dysfunct ion amo ng newer antidepressants. J Clin Psychiatry  
2002;63(4):357 -66.
6.Delgado PL, Brannan SK, Mallinckrodt CH, Tran PV, McNamara RK, Wang F, et al. Sexual 
funct ioning assessed in 4 double -blind placebo -and paroxetine -controlled tri als of dulo xetine 
for major depressive disorder. J Clin Psychiatry  2005;66(6):686 -92.
7.Clayton A, Kornstein S, Prakash A, Mallinckrodt C, Wohlreich M. Changes in sexual 
funct ioning associated with duloxet ine, escitalopram, and placebo in the treatment of patients 
with major depressive disorder. J Sex Med 2007;4(4 Pt 1):917- 29.
8.Roose SP. Toler abilit y and patient compliance. J Clin Psychiatry 1999;60 Suppl 17:14 -7; 
discussio n 46-8.
9.Rothschild AJ. Sexual side effects of ant idepressants. J Clin Psychiatry 2000;61 Suppl 
11:28 -36.
10.Zajecka JM. Clinical issues in lo ng-term treatm ent wi th antidepressants. J Clin Psychiatry  
2000;61 Suppl 2:20 -5.
11.Hu XH, Bull SA, Hunkeler EM, Ming E, Lee JY, Fireman B, et al. Incidence and duration of 
side effects and those rated as bothersome with selective serotonin reuptake inhibitor treatm ent 
for depressio n:patient report versus physician est imate. J Clin Psychiatry  2004;65(7):959 -65.
12.Papakostas GI. Tolerabilit y of modern ant idepressants. J Clin Psychiatry 2008;69 Suppl 
E1:8 -13.
13.Montejo -Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A, Bousono M, Calce do A, et al . 
SSRI -induced sexual dysfunct ion: fluoxet ine, paroxet ine, sertraline, and fluvoxamine in a 
prospective, mult icenter, and descript ive clinical study  of 344 pati ents. J Sex Mari tal Ther 
1997;23(3):176 -94.
Vortioxetine
Study No. Vortioxetine -4001 Page 74of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL14.Clayton AH, Montejo AL. Major depress ive disorder, antidepressants, and sexual dysfunct ion. 
J Clin Psychiatry  2006;67 Suppl 6:33-7.
15.Bang -Andersen B, Ruhland T, Jorgensen M, Smith G, Frederiksen K, Jensen KG, et al. 
Discovery  of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA2100 4): a novel 
multimodal com pound for the treatm ent of m ajor depressive disorder. J Med Chem 
2011;54(9):3206 -21.
16.Westri ch L, Pehrson A, Zhong H, Nielsen SM, Frederickson K, Stensbo l TB, et al. In vitro and 
in vivo effects of the mult imodal and antidepres sant vortioxet ine (Lu AA21004) at human and 
rat targets. Int J Psy chiatry  Clin Pract 2012;16((Suppl 1)):47. Abstract No. P 71.
17.TRINTELLIX (vortioxet ine) Tablets. Package Insert. Deerfield, IL: Takeda Pharmaceuticals 
America, Inc., May  2016.
18.Boul enger JP, Loft H, Florea I. A rando mized clinical study of Lu AA21004 in the preventio n 
of relapse in pat ients with major depressive disorder. J Psy chopharmaco l 
2012;26(11):1408 -16.
19. Jacobsen PL, Mahableshwarkar AR, Chen Y, Chrones L, Clayton AH. Effect of vorti oxetine 
vs escitalopram on sexual funct ioning in adults wit h well -treated m ajor depressive disorder 
experiencing SSRI -induced sexual dysfunct ion. J Sex Med 31 Aug 2015. 
doi:10.1111/j sm.12980.
20.Clayton AH, McGarvey  EL, Clavet GJ. The Changes in Sex ual Functioning Quest ionnaire 
(CSFQ): development, reliabilit y, and validit y. Psychopharmaco l Bull 1997;33(4):731 -45.
21.Yalcin I, Bum p RC. Validati on of  two gl obal impressio n quest ionnaires for incont inence. Am 
J Obstet Gyneco l 2003;189(1):98 -101.
22.Posner K, Oquendo MA, Gould M, Stanley B, Davies M. Columbia Classificat ion Algorithm 
of Suicide Assessment (C -CASA): classificat ion of suicidal events in the FDA's pediatric 
suicidal risk analysis of ant idepressants. Am J Psychiatry 2007;164(7):1035-43.
23.Posner K, Melvin GA, Stanley  B, Oquendo MA, Goul d M. Factors in the assessment of 
suicidality in youth. CNS Spectr 2007;12(2):156- 62.
Vortioxetine
Study No. Vortioxetine -4001 Page 75of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAppendix ASchedule of Study Procedures
Study Day/Week:Screening
PeriodBase -
line Double -Blind Treatment PeriodFinal Visit/
ET Visit (a)Follow -up
Contact (b)
Days
-28 to -1 Day 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 7
Visit Windows (Days Relative to 
Baseline [Day 0]): 0 ±3 ±3 ±3 ±3 ±3 ±5
Visit Number: 1 2 3 4 5 6 7
Screening/Baseline Procedures
Informed consent X
Subject registry database X
Demographics, medical and/or 
psychiatric history, medication historyX
Height, BMI X
ECG X
HBsAg, HCV, HIV, free testosterone, 
TSH, free T4, HbA1c (c) X
Urine drug screen X X
Concurrent medical and psychiatric 
conditionsX X (d)
Inclusion/exclusion criteria X X (d)
Eligibility verification X X (e)
Safety Assessments
Physical examination, weight X X X
Vital signs X X X X
Concomitant medications X X X X X X X X
Hematology, serum chemistry, 
urinalysisX X (f) X (f)
C-SSRS X X X X X X X
PTE assessment (g) X X
AE assessments (h) X X X X X X
Pregnancy test (hCG) (i) X X X X X X X
Sexual Functioning Assessments
CSFQ -14 (j) X X X X X X X
PGI-I (j) X X X X X
Other Blood Sampling
PK sample collection (k) X X X
DNA PGx sample collection (l) X
RNA PGx sample collection (m) X X
Clinical Supplies
Contact IWRS for subject ID/ 
medication ID/subject statusX X X X X X X
Vortioxetine
Study No. Vortioxetine -4001 Page 76of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALStudy Day/Week:Screening
PeriodBase -
line Double -Blind Treatment PeriodFinal Visit/
ET Visit (a)Follow -up
Contact (b)
Days
-28 to -1 Day 0 Week 1 Week 2 Week 3 Week 4 Week 5 Week 7
Study  drug compliance technology X X X X X X
Dispense study drug X (n) X X X X
Study  drug return/accountability/ 
complianceX X X X X
(a) Final Visit procedures to be conducted for subjects who withdraw early, except for those who withdraw their consent and r efuse 
further contact. 
(b) The Follow -up Contact will be conducted by telephone. 
(c) TSH to be measured at Screening to exclude subjects with clinically significant thyroid dysfunction (hyperthyroidism or 
hypothyroidism), which may impact sexual functioning. If TSH value is outside the normal range, free T4 will be measured.
(d) To be updated at Baseline.
(e) A prerandomization form must be approved by the  medical monitor prior to randomization.
(f) Blood samples for clinical laboratory tests to be collected under fasting conditions at Baseline and Week 5/ET.
(g) PTEs to be as sessed from the date of Screening up to the first dose of study drug on Day 1.
(h) AEs to be assessed daily from the first dose of study drug on Day 1 until the Follow -up Contact at Week 7.
(i) Serum test at Screening and urine test at all other visits. Fo r women of child -bearing potential only.
(j) The subject should complete the CSFQ -14 before the PGI-I.
(k)Six PK blood samples to be collected for each subject (2 samples at each time point at Weeks 3, 4, and 5/ET) for measureme nt of 
plasma vortioxetine or paroxetine concentrations. At Week 5/ET, the blood sample will be collected at the same time point as the 
blood sample for clinical laboratory tests. Subjects will be instructed to take the study drug immediately after collection o f the PK 
blood sample. 
(l) One 6 -mL whole blood sample to be collected for DNA isolation predose at Baseline (Day 0) from each subject.
(m) Two 2.5 -mL whole blood samples to be collected for RNA isolation predose at Baseline (Day 0) and also at Week 5/ET from 
each subject (ie, 4 samples per subject).
(n) Subjects are to be instructed to take the first dose of study drug on the morning of Day 1 (morning after Baseline).
PPD
Vortioxetine
Study No. Vortioxetine -4001 Page 77of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAppendix BResponsibilities of the Investigator
Clinical research studies sponsored by  the sponsor are subject to ICH GCP and all the applicable 
local laws and regulat ions. The responsibilit ies imposed on invest igators by  the FDA are 
summarized in the “Statement of Invest igator” (Form FDA 1572), which m ust be com pleted and 
signed before the invest igator may participate in this study . 
The invest igator agrees to assume the fo llowing responsibilit ies by signing a Form FDA 1572:
1.Conduct the study  in accordance wit h the protocol.
2.Personally conduct or superv ise the staff who will assist in the protocol.
3.Ensure that study related procedures, including study specific (non routine/non standard panel) 
screening assessments are NOT performed on potent ial subjects, prior to the receipt of written 
approval  from relevant governing bodies/authorit ies.
4.Ensure that all co lleagues and emplo yees assist ing in the conduct of the study are informed of 
these obligat ions.
5.Secure prior approval of the study  and any  changes by  an appropri ate IRB that conform to 
21Code of Federal Regulati ons (CFR) Part 56, ICH, and local regulatory  requi rements.
6.Ensure that the IRB will be responsible for init ial review, continuing review, and approval of 
the protocol. Promptly report to the IRB all changes in research activit y and all ant icipated
risks to subjects. Make at least yearly reports on the progress of the study to the IRB and issue 
a final report within 3 months of study  com pletion.
7.Ensure that requirements for informed consent, as outlined in 21 CFR Part 50, ICH and local 
regul ations, are m et.
8.Obtain valid informed consent from each subject who participates in the study , and docum ent 
the date of consent in the subject’s medical chart. Valid informed consent is the most current 
versio n approved by the IRB. Each informed consent form shou ld contain a subject 
authori zation sect ion that describes the uses and disclosures of a subject’s personal 
inform ation (including personal health informat ion) that will take place in connect ion wit h the 
study . If an informed consent form does not include s uch a subject authorization, then the 
investigator must obtain a separate subject authorization form from each subject.
9.Prepare and maintain adequate case histories of all persons entered into the study , incl uding 
eCRFs, hospital records, laboratory  resul ts, etc, and maintain these data for a minimum o f 
2years fo llowing notificat ion by the sponsor that all invest igations have been discont inued or 
that the regulatory  authori ty has approved the marketing applicat ion. The invest igator should 
contact and recei ve written approval fro m the sponsor before disposing o f any such 
docum ents.
10.Allow possible inspection and copying by the regulatory  authori ty of GCP -specified essent ial 
docum ents.
Vortioxetine
Study No. Vortioxetine -4001 Page 78of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALMaintain current records of the receipt, administratio n, and disposit ion ofsponsor -supplied drugs, 
and return all unused sponsor-supplied drugs to the sponsor.
11.Report adverse reactions to the sponsor prompt ly. In the event of an SAE, notify the sponsor 
within 24 hours.
Vortioxetine
Study No. Vortioxetine -4001 Page 79of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAppendix CElements of the Subject Informed Consent 
In seeking informed consent, the fo llowing information shall be provided to each subject:
1.A statement that the study  involves research.
2.An explanat ion of the purposes of the research.
3.The expected duration of the subject’s partici pation.
4.A descript ion of the procedures to be fo llowed, including invasive procedures.
5.The i dentificat ion of any  procedures that are experimental.
6.The est imated number of subjects invo lved in the study .
7.A descript ion of the subject’s responsibilit ies.
8.A descript ion of the conduct of the study .
9.A statement describing the treatment(s) and the probabilit y for random  assignment to each 
treatm ent.
10.A descript ion of the possible side effects of the treatment that the subject may receive.
11.A descript ion of any  reasonably  foreseeable ri sks or di scomf orts to the subject and, when 
applicable, to an embry o, fetus, or nursing infant.
12.A descript ion of any  benefi ts to the subject or to others that reasonably  may be expected from  
the research. When there is no intended clinical benefit to the subject, the subject should be 
made aware of this.
13.Disclosures o f appropriate alternat ive procedures or courses of treatment, if any, that might be 
advantageous to the subject and their important potent ial risks and benefits.
14.A stat ement describing the extent to which confident iality of records i dentifying the subject 
will be maintained, and a note of the possibilit y that regulatory  agencies, audi tor(s), IRB, and 
the mo nitor may inspect the records. By signing a written informed cons ent form, the subject is 
authori zing such access.
15.For research invo lving more than minimal risk, an explanat ion as to whether any co mpensatio n 
and an explanat ion as to whether any  medical treatments are available if injury  occurs and, if 
so, what they  cons ist of or where further informat ion may be obtained.
16.The ant icipated prorated payment(s), if any, to the subject for participat ing in the study.
17.The ant icipated expenses, if any , to the subject for parti cipat ing in the study.
18.An explanat ion of whom to cont act for answers to pertinent questions about the research 
(invest igator), subject’s rights, and IRB and who m to contact in the event of a research -related 
injury  to the subject.
Vortioxetine
Study No. Vortioxetine -4001 Page 80of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL19.A statement that participation is vo luntary, that refusal to participate will involve no penalt y or 
loss of benefits to which the subject otherwise is entit led, and that the subject may discont inue 
participat ion at any  time wi thout penal ty or loss of benefits to which the subject is otherwise 
entitled.
20. The consequences of a subject’ s decisio n to wi thdraw from  the research and procedures for 
orderly terminat ion of part icipation by the subject.
21.A statement that the subject will be informed in a timely manner if informat ion beco mes 
available that may be relevant to the subject’s willing ness to continue participat ion in the 
study .
22.A statement that results of PGx analysis will not be disclosed to an individual, unless 
prevailing laws require the sponsor to do so.
23.The foreseeable circumstances or reasons under which the subject’s participat ion in the study  
may be terminated.
24.A wr itten subject authorization (eit her contained within the informed consent form or provided 
as a separate document) describing to the subject the contemplated and permissible uses and 
disclosures of the subject’s pers onal information (including personal health informat ion) for 
purposes of conduct ing the study. The subject authorizat ion must contain the fo llowing 
statements regarding the uses and disclosures of the subject’s personal informat ion:
a)that personal informati on (incl uding personal healt h informat ion) may be processed by  or 
transferred to other parties in other countries for clinical research and safet y reporti ng 
purposes, including, without limitat ion, to the fo llowing: (1) Takeda, its affiliates, and 
licensin g partners; (2) business partners assist ing Takeda, its affiliates, and licensing 
partners; (3) regulatory  agencies and other healt h authorities; and (4) IRBs;
b)it is possible that personal informat ion (including personal healt h informat ion) may be 
processe d and transferred to countries that do not have data protection laws that offer 
subjects the same level o f protecti on as the data protection laws wit hin this country; 
however, Takeda will make every  effort to keep y our personal  information confident ial, 
and your name will not be di sclosed outsi de the clinic unless required by law;
c)that personal information (including personal healt h informat ion) may be added to 
Takeda’s research databases for purposes of developing a better understanding of the 
safet y and e ffectiveness o f the study  drug(s), studying other therapies for patients, 
developing a better understanding of disease, and improving the efficiency of future 
clinical studies;
d)that subjects agree not to restrict the use and disclosure of their personal in formation 
(including personal healt h informat ion) upon withdrawal fro m the study  to the extent that 
the restricted use or disclosure of such informat ion may  impact the scient ific integrity of 
the research; and
Vortioxetine
Study No. Vortioxetine -4001 Page 81of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALe)that the subject’s ident ity will remain confid ential in the event that study  resul ts are 
published.
25.Female subjects of childbearing potential (eg, nonsterilized, premenopausal female subjects) 
who are sexually  active m ust use adequate contraception (as defined in the informed consent) 
from Screening t hroughout the duration o f the study and for 30 days after the last dose of study 
drug. Regular pregnancy tests will be performed throughout the study for all female subjects of 
childbearing potential. If a subject is found to be pregnant during study , stud y drug will be 
discontinued and the invest igator will o ffer the subject the choice to receive unblinded 
treatm ent information.
26.A statem ent that clinical trial informat ion fro m this trial will be publicly disclo sed in a publicly 
accessible website, such as ClinicalTrials.gov.
Vortioxetine
Study No. Vortioxetine -4001 Page 82of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAppendix DInvestigator Consent to Use of Personal Information
Takeda will co llect and retain personal information of invest igator, including his or her name, 
address, and other personally identifiable inf ormation. In addit ion, invest igator’s personal 
inform ation may be transferred to other parties located in countries throughout the world (eg, the 
United Kingdom, United States, and Japan), including the following:
Takeda, its affiliates, and licensing part ners.
Business partners assist ing Takeda, its affiliates, and licensing partners.
Regulatory  agencies and other health authorit ies.
IRBs.
Invest igator’s personal informat ion may be retained, processed, and transferred by  Takeda and 
these other parties for research purposes including the fo llowing:
Assessment of the suitabilit y of invest igator for the study  and/or other clinical studies.
Management, monitoring, inspect ion, and audit of the study .
Analysis, review, and verificat ion of the study  results.
Safety reporti ng and pharmacovigilance relat ing to the study .
Preparati on and submissio n of regulatory  filings, correspondence, and communicat ions to 
regul atory  agencies rel ating to the study .
Preparati on and submissio n of regulatory  filings, correspondence, an d communicat ions to 
regul atory  agencies relat ing to other medications used in other clinical studies that may contain 
the sam e chemical com pound present in the study  drug.
Inspect ions and invest igations by regulatory  authorit ies relat ing to the study.
Self-inspect ion and internal audit within Takeda, its affiliates, and licensing partners.
Archiving and audit of study  records.
Posting investigator site contact informat ion, study details and results on publicly accessible 
clinical trial registries, databases , and websi tes.
Invest igator’s personal informat ion may be transferred to other countries that do not have data 
protecti on laws that offer the same level of protection as data protection laws in invest igator’s own 
country .
Invest igator acknowledges and con sents to the use of his or her personal information by  Takeda 
and other parties for the purposes described above.
Vortioxetine
Study No. Vortioxetine -4001 Page 83of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAppendix ECollection, Storage, and Shipment of Pharmacokinetic Samples
Instructions for processing of plasma s amples for pharmacokinetic analysis of vortioxetine 
and paroxetine
1.Collect 6 -mL of venous blood into a chilled Becton -Dickinson Vacutainer containing 
K2EDTA (for vorti oxetine) or sodium heparin (for paroxetine).
2.Gent ly invert the Vacutainer several t imes t o mix the addit ive with the collected blood prior to 
centrifugation and place immediately on ice.
3.Centrifuge the Vacutainers for 10 minutes at approximately 1100 to 1300 relative centrifugal 
force (RCF) at approximately  4°C in a refri gerated centrifuge. No te: If using a collect ion 
device other than a Becton -Dickinson Vacutainer refer to manufacturer’s instruction for proper 
centrifugation force and t ime.
4.Immediately fo llowing centrifugat ion, gent ly remove plasma fro m the packed cells. To ensure 
a more hom ogeneous sample, all plasma for each analyte should first be transferred into 1 
aliquot. From there, split the plasma evenly between the 2 aliquots. A minimum o f 1.2 mL 
needs to be obtained for each sample. Labeling may include protocol number 
Vorti oxetine -4001, m atrix (pl asma), subject ID (XXXX -XXX), nominal day and time, and 
either “SET 1” (for ori ginal  sample) or “SET 2” (for duplicate sample).
5.Cap the labeled storage tubes and freeze the plasma samples immediately at approximately 
-20°C or lower. No more than 60 minutes should elapse between blood collect ion and freezing 
the plasma sample.
6.Keep samples frozen at approximately -20°C or lower until shipment to the central laboratory. 
Shipping of plasma for vortioxetine or paroxetine quantification
The fo llowing instructi ons are recommended unless they  differ from  the si te’s standard operating 
procedures for labeling, packaging, or shipping o f PK samples. 
1.Biological samples (pl asma) shoul d be shipped on dry  ice to prevent thawing during transit. 
Samples shou ld be shipped only on Monday, Tuesday, or Wednesday, and at least 2 days prior 
to a national ho liday, in order to minimize the possibilit y of samples in transit over a weekend 
or holiday. If duplicate samples are to be shipped, send SET 1 samples and await confirmat ion 
of arrival before shipping the duplicate SET 2 samples. Samples may be shipped on other days 
with the permissio n of the sponsor.
2.Before shipping, make sure the sample tubes are tight ly sealed. Separate each subject’s 
samples as fo llows:
3.Separate the duplicate SET 2 samples from the SET 1 samples.
4.Place SET 1 samples for each subject into a self -sealing bag (eg, Ziploc) containing addit ional 
absorbent material.
Vortioxetine
Study No. Vortioxetine -4001 Page 84of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIAL5.Using a permanent marker, write the subject ID, study  drug (vorti oxetine or par oxetine), 
sample m atrix (pl asma), number of samples, and “SET 1” on each self- sealing bag.
6.Place the bags of individual subject’s samples into a larger plast ic bag so that samples are 
doubl e bagged. Duplicate SET 2 samples should be returned to the freezer for storage. Repeat 
steps 3 through 6 above when preparing duplicate samples for shipment, except self -sealing 
bags should be marked “SET 2”.
7.An inventory  of individual  samples shoul d acco mpany each shipment and should include the 
sponsor’s name (Takeda), protocol number (Vortioxet ine-4001), invest igator’s name, sample 
type (pl asma), subject ID, nominal collect ion day  and time, and intended sample storage 
condi tions. When duplicate SET 2 samples are being shipped, make a copy of the original SET 
1 sam ple inventory  and m ark as “SET 2”. Place the inventory  paperwork into a l arge 
self-sealing bag. SET 1 samples will be shipped first on dry  ice, fo llowed by  shipment of 
duplicate SET 2 samples after SET 1 samples have been received by the central laboratory .
8.Forsample packing, use dry ice generously (eg, 20 to 25 pounds per day of transit) to 
safeguard against longer than expected shipping times and delays. Use newspaper or other 
materi al to insulate the doubl e-bagged samples from direct contact with the dry  ice. Place the 
sample bundles into a polyst yrene (eg, Sty rofoam) container (or other suitable container) and 
fill the excess space wit h dry  ice slabs or i ce pellets (preferably  the l atter). Make a note of the 
estimated weight of the dry  ice used per shipping container.
9.Place the inventory  paperwork (in a large self -sealing bag) on top of the dry  ice in the 
polyst yrene container. Place the lid on the polyst yrene container and seal co mpletely wit h 
strapping tape. Place the polyst yrene container in a cardboard sh ipping carton and seal 
securely  with strapping tape.
10.Mark the outside of shipping carton(s) with a tally number (1 of 5, 2 of 5, etc). 
11.Affix an address label to each shipping carton. Use the preprinted air waybills provided by the 
central  laboratory . 
12.Obtain the air waybill number and a receipt of shipment fro m the carrier.
Vortioxetine
Study No. Vortioxetine -4001 Page 85of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALAppendix FDetailed Description of Amendments to Text
The primary sect ion(s) of the protocol affected by the changes in Amendment No. 01are indicated. 
The corresponding text has been revised throughout the protocol.
Change 1:Clarify inclusio n and exclusio n criteria.
The primary  change occurs in Section s7.1Inclusion Criteria and 7.2Exclusio n Cri teria: 
Initial 
wording:Inclusio n criterion #4: The subject has been in a steady relat ionship for ≥3months and 
plans to rem ain in that rel ationship for the duration of the study , and is current ly 
sexually  active (≥2times per week).
Inclusio n criterion #6: If female, the subject has a regular menstrual cy cle.
Exclusio n criterion #12: The subject has a history  of depressio n or any  other 
psychiatric illness.
Exclusio n criterion #15: The subject has had a surgical or medical procedure on 
reproducti ve/geni tourinary  organs (excluding uncomplicated vasectomy  and tubal  
ligation).
Exclusio n criterion #21: The subject has a history  of or current alcohol or other 
substance abuse or dependence.
Amended 
or new 
wording:Inclusio n criterion #4: The subject has been in a steady relat ionship for ≥3months and 
plans to rem ain in that rel ationship for the duration of the study , and is current ly 
sexually  active ( ≥2times per week). Note: Partners are not allowed to enroll in th is 
trial.
Inclusio n criterion #6: If female, the subject has a regular menstrual cy cle (note: 
amenorrhea resulting from hormonal contraceptives is not exclusionary) . 
Exclusio n criterion #12: The subject has a history  of depressio n or any  other 
psychiatric illness including sleep disorders and premenstrual dysphoric 
disorder .
Exclusio n criterion #15: The subject has had a surgical or medical procedure on 
reproducti ve/geni tourinary  organs (excluding uncomplicated cesarean section 
(C-section), vasectomy, and tubal  ligat ion that do not impact sexual functioning ).
Exclusio n criterion #21: The subject has a history  of or current alcohol or other 
substance abuse or dependence (according to Diagnostic and Statistical Manual of 
Mental Disorders, Fourth Edition, Text Revised [DSM -IV-TR] criteria) .
Vortioxetine
Study No. Vortioxetine -4001 Page 86of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALRationale for Change :
Inclusio n and exclusio n criteria were revised to provide further specificit y in response to questions 
from invest igators about eligibilit y. 
The fo llowing sect ion also contain sthis change:
Secti on 2.0STUDY SUMMARY .
Change 2: Update, correct, or clarify excluded medicat ions and treatments .
The primary  change occurs in Secti on7.3Excluded Medicat ions and Treatments , Table 7.a
Excluded Medicat ions and Treatments : 
Descript ion 
of changes:Chronic use of NSAIDs is excluded only after Baseline, not excl uded for 3 m onths 
prior to Baseline . Furtherm ore,episodic use is allo wed: up to 2 doses of ibuprofen 
or naproxen per week is allowed. Aspirin is NOT allowed .
Added :antineoplastics are d isallowed for 3 months Prior to/From Baseline
(already  disall owed during the study  as ei ther chronic or epi sodic use).
Melatonin and topical steroids are not excluded before or during the study .
Rationale for Change :
The short half life of NSAIDs does not require a 3 -month washout period and occasional use o f 
ibuprofen or naproxen will not affect sexual funct ion. Aspirin continues to be disallowed as it is 
counterindicated with paroxetine. Due to potential length of washout, antineoplast ics must be 
stopped at least 3 months prior to start of study. Use of melatonin and topical steroids are allowed 
as they  are not expected to affect sexual funct ion.
Vortioxetine
Study No. Vortioxetine -4001 Page 87of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALChange 3:Add that psychiatric history will be assessed as well as medical history .
The primary  change occurs in Section 9.1.3 Demographics, Medical History , Psy chiatri c History , 
and Medication History  Procedure :
Initial 
wording:Medical history  to be obtained will include determining whether the subject has any  
significant condit ions or diseases relevant to the disease under study that stopped at or 
prior to si gning of informed consent. Ongoing condit ions are considered concurrent 
medical condit ions.
Amended 
or new 
wording:Medical history and psychiatric history  to be obtained will include determining 
whether the subject has any  significant condi tions or di seases rel evant to th e disease 
under study  that stopped at or prior to signing of informed consent. Ongoing medical
and/or psychiatric condi tions are considered concurrent medicalcondi tions.
Rationale for Change :Change made to clearly outline that an assessment of psychiat ric disorders 
is required as they  are exclusio nary and may  have an effect on the study  outcom e. 
The fo llowing sect ions also contain this change:
Secti on 9.1.11 Documentation of Concurrent Medical and/or Psychiatric Condit ions. 
Appendix A Schedule of Study  Procedures .
Change 4:Add instructions on the order in which the scales Changes in Sexual Funct ioning 
Quest ionnaire Short -Form (CSFQ -14) and Pat ient Global Im pressi on of Improvement (PGI -I) 
shoul d be com pleted .
The primary  change occur sin Section 9.1.8.1 CSFQ -14:
Added text: The subject should complete the CSFQ -14 scale before the PGI -I scale at all 
post-baseline visits.
Rationale for Change: The PGI -Iis a global assessment which is more appropriate to complete 
after the specific quest ionnaire on sexual funct ioning (CSFQ -14).
The fo llowing sect ions also contain this change:
Secti on 9.1.8.2 PGI-I Scal e
Appendix A Schedule of Study  Procedures , footnote (j) .
Vortioxetine
Study No. Vortioxetine -4001 Page 88of 88
Protocol Incorporating Amendment No. 01 10 January 2017
CONFIDENTIALChange 5:Update personnel changes .
The primary  change occurs in Section 1.1Contacts and Section 1.2Approval :
Initialwording:
Responsible Medical Office
Amended or new wording:
Initial 
wording:
Signatures
Amended 
or new 
wording:
Rationale for Change: A new responsible medical mo nitor/signatory  was installed.
PPD
PPD
PPD
PPD
    
 
  
 
  
 
ELECTRONIC SIGNATURES  
Signed by Meaning of Signature Server Date 
(dd-MMM-yyyy HH:mm ‘UTC’) 
   
  
   
  
   
  
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
   
 
   
 
090101d6805250a2A Randomized, Double-Blind, Parallel Group, Placebo- and Active-Controlled, Phase 4 Study Evaluating the
Effect of Vortioxetine 10 and 20 mg/day vs Paroxetine 20 mg/day on Sexual Functioning in Healthy Subjects
Clinical Science Approval 11-Jan-2017 17:16 UTC
Clinical VP Approval 11-Jan-2017 18:14 UTC
Biostatistics Approval 12-Jan-2017 13:31 UTC
PPD